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Summary 
Translational regulation of mRNA is an important mechanism by which cells modulate 
protein synthesis. The mRNAs that encode for secreted proteins or proteins of the 
endomembrane system are translated at the endoplasmic reticulum (ER). In 
Saccharomyces cerevisiae, Brefeldin A resistance factor 1 protein (Bfr1p) was first 
identified as a multi-copy suppressor of Brefeldin A and proposed to have a function 
in the secretory pathway. Although BFR1 is a non-essential gene, bfr1Δ cells show 
several defects, including altered cell shape and size, change in ploidy, induction of 
P-bodies and chromosomal mis-segregation. However, later studies have shown 
Bfr1p as a component of polysomes, binding to several hundred mRNAs at the ER 
and most of these mRNAs encode for secretion or endomembrane proteins. Despite 
Bfr1p lacking canonical RNA-binding domains, an in vivo UV-crosslink of Bfr1p with 
RNA revealed six residues in Bfr1p that are cross-linked with the RNAs. These studies 
suggest a potential role of Bfr1p in translational control of mRNAs, however its 
molecular function remains elusive to date. 
In this present study, I show that the Bfr1p’s localization to the ER is RNA-dependent 
and that a point mutation in the RNA-binding residue F239 of Bfr1p alone is enough 
to affect this localization. Further, I show that the roles of Bfr1p in ploidy maintenance, 
P-bodies induction and brefeldin A resistance are independent of its interaction with 
RNA. Consistent with the previous studies, I show that Bfr1p binds to ERG4 mRNA, 
which encodes an enzyme involved in the final step of ergosterol biosynthesis and that 
the RNA-binding mutants of Bfr1p impede this binding. Although ERG4 mRNA 
localizes to the ER in bfr1Δ cells, the levels of Erg4 protein is strongly reduced, 
possibly due to its misfolding and subsequent re-translocation to the cytoplasm for 
degradation via the ERAD pathway. Using ribosome affinity purification (RAP) and 
 vi 
 
polysome profiling, I demonstrate a reduction in the total ribosomal occupancy on the 
ERG4 mRNA in bfr1Δ cells and an increased ratio of monosomes to polysome in RNA-
binding mutants of Bfr1p, suggesting a role  for Bfr1p in translational elongation or 
protein translocation of the mRNAs that are translating at the ER. Taken together, this 
study provides further evidence of the proposed role of Bfr1p in translational control 
with separation from its function in ploidy maintenance.   
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Zusammenfassung 
Die translationale Regulation von mRNA ist ein wichtiger Mechanismus, durch den 
Zellen die Proteinsynthese modulieren. Die mRNAs, die für sekretierte Proteine oder 
Proteine des Endomembransystems kodieren, werden am endoplasmatischen 
Retikulum (ER) translatiert. In Saccharomyces cerevisiae wurde das Brefeldin A 
Resistenzfaktor 1 Protein (Bfr1p) erstmals als Mehrfachkopiesuppressor von Brefeldin 
A identifiziert und eine Funktion im Sekretionsweg vorgeschlagen. Obwohl BFR1 ein 
nicht essentielles Gen ist, zeigen die bfr1Δ Zellen verschiedene Phänotypen, 
beispielsweise eine veränderte Zellform und Zellgröße, Änderung der Ploidie, 
Induktion von P-bodies und Chromosomenfehlsegregation. Spätere Studien haben 
jedoch gezeigt, dass Bfr1p als Bestandteil von Polysomen an verschiedene mRNAs 
im ER bindet und die Mehrheit dieser mRNAs für Sekretions- oder 
Endomembranproteine kodiert. Obwohl Bfr1p keine kanonischen RNA-
Bindungsdomänen aufweist, ergab eine UV-crosslink, das die RNA in vivo über sechs 
Aminosäurereste. Diese Studien legen nahe, dass Bfr1p eine potenzielle Rolle bei der 
Translationskontrolle von mRNAs spielt. Die molekulare Funktion von Bfr1 ist bis 
heute nicht bekannt.  
In dieser vorliegenden Studie zeige ich, dass die Bfr1p Lokalisierung zum ER RNA-
abhängig ist und eine Punktmutation F239 von Bfr1p ausreicht, um diese 
Lokalisierung zu beeinflussen. Außerdem zeige ich, dass die Rolle von Bfr1p bei der 
Aufrechterhaltung der Ploidie, der Induktion von P-bodies und der Brefeldin A-
Resistenz von seinen RNA Wechselwirkungen unabhängig ist. In Übereinstimmung 
mit den vorherigen Studien zeigte sich, dass Bfr1p an die ERG4 mRNA bindet, die für 
ein Enzym kodiert, das im letzten Schritt der Ergosterol-Biosynthese beteiligt ist, und 
dass die RNA-bindenden Mutanten diese Bindung beeinflussen. Obwohl ERG4 
 viii 
 
mRNA in bfr1Δ Zellen im ER lokalisiert ist, ist der Gehalt an Erg4p möglicherweise 
aufgrund der Fehlfaltung und dem Abbau über den ERAD Weg im Zytoplasmastask 
verringest. Mit den Experimenten zur Ribosomenaffinitätsreinigung (RAP) und 
Polysomenprofilierung konnte eine Verringerung der gesamten ribosomalen Belegung 
der ERG4 mRNA in bfr1Δ Zellen und ein erhöhtes Verhältnis von Monosomen zu 
Polysomen in RNA-bindenden Mutanten von Bfr1p nachgewiesen warden. Dies 
deutet auf eine Rolle von Bfr1p in der Translationselongation hin/oder korrekte Protein 
Translokation die am ER werden. Zusammengefasst liefert diese Studie weitere 
Beweise für die oben erwähnten Rolle von Bfr1p bei der Translationskontrolle, wobei 
Bfr1 ebenfalls einen Einfluss auf die Flufrechterhaltung der Ploidie hat. 
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1. Introduction 
1.1. The RNA-binding proteins  
RNA-binding proteins (RBPs) play important roles in different cellular processes such 
as gene expression, RNA trafficking, translation, and RNA stability. It is predicted that 
the proteomes of bacteria, archaea, and eukaryotes comprise approximately 3% to 
11% of RBPs and in Saccharomyces cerevisiae, nearly 500 proteins are predicted to 
function as RBPs (Scherrer et al. 2010). RBPs bind to double or single-stranded RNA 
to form ribonucleoprotein particles (RNPs). These proteins are present in both 
cytoplasm and nucleus. For example, in the nucleus, mRNAs can assemble with RBPs 
to form mRNP complexes that are exported to the cytoplasm for their translation or 
degradation. Therefore, RBPs can regulate gene expression in the nucleus and 
furthermore can control the process of localization, translation, and stability of these 
mRNAs in the cytoplasm. 
Several RBPs have been implicated in neurological diseases. The fragile X mental 
retardation syndrome is caused by a mutation in the KH2 domain (isoleucine304 to 
asparagine) of the RNA-binding protein FMRP (Boulle et al. 1993 and Feng et al. 
1997). FMRP is responsible for regulating the local translation of proteins involved in 
synaptic development. FMR1 knock-out mice show excessive protein production in 
the brain due to the loss of FMRP which acts as a negative regulator of translation 
(Feng et al. 1997). Similarly, mutations in the SMN1 gene causes Spinal Muscular 
Atrophy (SMA) in humans. SMN (Survival of Motor Neurons) proteins are chaperones 
and highly conserved from the fission yeast Schizosaccharomyces pombe SMN 
proteins are crucial for the efficient assembly of Sm proteins and small nuclear RNAs 
(snRNAs) into snRNPs (Liu et al. 1997). SMN proteins bind to upstream of several 
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RBPs and regulate the splicing process of several RNAs (Chaytow et al. 2018). Recent 
studies have demonstrated that specific RBPs that contain low-complexity regions and 
prion-like domains such as TDP-43 and FUS proteins are concentrated by liquid-liquid 
phase separation in the cytoplasm (Schmidt et al. 2019, Niaki et al. 2019). These 
proteins form self-templating fibrils and can cause several neurological diseases such 
as amyotrophic lateral sclerosis and frontotemporal dementia (Shorter 2019).  
RBPs are also involved in several other diseases such as cancer. For example, LARP 
family proteins contain a conserved La domain, and are upregulated in cancers of the 
head and neck (Sommer et al. 2010). Also, the RBP hnRNP A1 enhances the early 
splicing of HPV16 mRNA by binding to its splicing silencer (Zhao et al. 2007). The 
alternative splicing of HPV16 mRNA encodes for a truncated version of E6*I transcript 
of a full length E6 oncoprotein and is commonly found in oropharyngeal cancers 
(Paget-Bailly et al. 2019). Lastly, the mRNA cap-binding protein eukaryotic initiation 
factor 4E (eIF4E) is highly upregulated in several cancers. A specific AU-rich element 
in the 3'-UTR of eIF4E binds to HuR (Hu family RNA-binding proteins) and stabilizes 
the mRNA and can correlate with enhanced expression of eIF4E and HuR in malignant 
cancer specimens (Topisirovic et al. 2009).  
Traditionally, it was thought that the protein and RNA interactions occur through well-
defined protein domains called RNA-binding domains (RBDs). However, recent 
developments in high-throughput studies of RNA-protein complexes revealed several 
proteins that could interact with the RNA even in the absence of these known canonical 
domains (Hentze et al. 2018). These advancements also shed more light on how 
intrinsically disordered regions and protein-protein complexes can mediate RNA-
protein interactions and play crucial roles in several cellular processes (reviewed in 
Hentze et al. 2018).  
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1.1.1. Conventional RNA-binding proteins 
In eukaryotes, the canonical RBDs are mainly categorized into four families, the RNA 
recognition motif (RRM) (Oubridge et al. 1994), the heterologous nuclear RNP K 
homology (KH) domain (Lewis et al. 2000), the double-stranded RNA-binding domain 
(dsRBDs) (Ryter and Schultz 1998), and zinc-finger domains (Lu et al. 2003). These 
RBDs can interact with more than one mRNA and thus allow to regulate several 
mRNAs by single RBP (Hogan et al. 2018). Here, I briefly described the structure and 
specificity of RRM and KH domains, two commonly studied RBDs. 
1.1.1.1. The RNA recognition motif (RRM) 
One of the largest groups of the well-studied RBDs are RRMs that can be found in 
0.5-1% of human genes (Venter et al. 2001). The RRM containing RBPs are involved 
in mRNA processing, the export of mRNA from the nucleus to the cytoplasm and RNA 
stability (Dreyfuss et al. 2002). The typical RRM consists of 90 amino acids and with 
a topology of β1-α1-β2-β3-α2-β4 and forms a four-stranded β-sheet folded against two  
 
 
 
 
 
 
 Figure 1. Interaction of RRM with single-stranded RNA/DNA. A). The schematic view of the 
arrangement of four β sheets in an RRM containing proteins. The highlighted green residues 
(FY) on β1 and β3 sheets contain two conserved RNP1 and RNP2 aromatic residues that 
facilitate interaction with the RNA. B). Structure of hnRNP A1 RRM2 interacting with single-
stranded telomeric DNA showing how β1 and β3 sheets can accommodate two nucleotides. 
The figure and the text are adapted from Cléry et al. (2008). 
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α-helices. These four-stranded β sheets facilitate the interaction of RRM with the 
single-stranded RNA target (Figure 1A and B). In general, proteins with RRM binds 
to more than three nucleotides and recognize longer stranded RNA. The secondary 
structure elements of the RRM that is β2–β3 loop and the β1–α1 loop can facilitate the 
binding of the additional RNA. Therefore, in this way, the plasticity of an RRM is 
achieved for several RNAs (Cléry et al. 2008).  
1.1.1.2. hnRNP K homology domains (KH domains) 
The KH domains were first identified in the heterogeneous nuclear ribonucleoprotein 
K homology (hnRNP K) protein and hence given the name KH domains. KH domains 
are highly conserved and present in archaea, bacteria, and eukaryotes (Valverde et 
al. 2008). A typical KH domain consists of 70 amino acids and is often found in multiple 
copies per protein. These domains are capable of binding RNA independently and 
thus are popular for multi-tasking functions (Nicastro et al. 2015). KH domains are 
classified into two types (type I and II), and both types have a three-stranded β-sheet  
                  Type I KH domain                                      Type II KH domain 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A cartoon representation of the folding and secondary structure of KH domains with 
three β-sheet and three α-helices. The core structure is represented in green colour (KH motif) 
and the connecting variable loop in grey colour and with conserved GXXG motif between α1 
and α2 loop. The figure and the text are adapted from Nicastro et al. (2015). 
packed against three α-helices. The topology of type I is arranged as β-α-α-β-β-α 
whereas type II is arranged as α-β-β-α-α-β with a signature mark of conserved motif 
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GXXG in both types (Figure 2). This arrangement allows KH domains to interact 
through hydrophobic interactions with non-aromatic residues and the sugar-phosphate 
backbone of the single-stranded RNA/DNA to bind GXXG loop either by hydrogen 
bonding, electrostatic interactions or shape complementary and the specificity is 
achieved by the conserved hydrophobic region  (Lunde et al. 2007).  
1.1.2. Unconventional RNA-binding proteins 
Methodological developments in capturing RNA-protein interactome led to the 
identification of several new unconventional RBPs. These new experimental 
approaches included the use of aptamer-tagged RNA as a bait coupled with Mass 
spectrometry (MS) (Butter et al. 2009), Photoactive ribonucleoside-enhanced 
crosslinking and immunoprecipitation (PAR-CLIP) (Hafner et al. 2010), and a PAR-
CLIP variant with high-resolution Photo-cross-linking coupled with high-resolution 
Mass spectrometry (Kramer et al. 2014). These methods revealed that RBPs can have 
a range of other primary functions than simply binding and regulating RNA, such as 
enzymatic catalysis or mediators of protein-protein interactions (Hentze et al. 2018).    
Among these newly identified unconventional RBPs are proteins with intrinsically 
disordered regions (IDRs) that contains a motif to bind RNA comprised of aromatic, 
polar residues such as Tyr together with Gly and Ser (G/S)Y(G/S) (Han et al. 2012, 
Kato et al. 2012). These residues usually are part of the hydrophobic core of proteins 
but when they are present on the surface, they can interact with the nucleobases and 
establish interactions with RNA. In in vitro experiments, it was demonstrated that 
proteins with this motif also could form protein aggregates and induces amyloid-fiber 
structures. In addition, they are involved in the separation of the liquid-liquid phase in 
vivo (Kato et al. 2012). Also, several studies have shown that phase separation 
properties of the hnRNP proteins are important for the formation of stress granules 
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and mutations in these proteins cause several neurological diseases (Xiao et al. 2019, 
Henning et al. 2015 and Murakami et al. 2015). 
One of the newly emerged unconventional RBDs is the Rossmann-fold (R-f) domain, 
which was especially identified in the proteomes of RNA-binding complexes from 
cardiomyocytes (Liao et al. 2016). These R-f domains consist of six-stranded parallel 
β sheets with the interlinking α helices on both sides of these sheets and they interact 
with mono-or dinucleotides that such as  ATP or GTP but can also bind to RNA 
(Caetano-Anollés et al. 2007, Hentze 1994, Rossmann et al. 1974).  
Although these recent studies have identified several new types of RNA-protein 
interactions, our understanding of the molecular details of these interactions or their 
biological function remains still unclear.  
1.2. The Endoplasmic reticulum, a factory for protein synthesis of secretion and 
endomembrane system 
The endoplasmic reticulum (ER) is one of the largest membrane-bound organelles of 
eukaryotic cells and made up of tubular structures and sheets that are spread 
throughout the cytoplasm (English and Voeltz 2013). The ER is the major site for the 
synthesis of secreted or endomembrane proteins (Rapoport 2007, Braakman and 
Hebert 2013, Reid and Nicchitta 2015, Hoffman et al. 2019), production of lipids and 
steroids, calcium storage (Clapham 2007), but also participates in the carbohydrate 
metabolism (Hebert et al. 2005, Fagone and Jackowski 2009). Its physical structure 
of tubules and sheets can change based on environmental influence and can these 
changes be important to regulate several functions in the cell (English and Voeltz 
2013). 
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The ER can be divided into two categories. The surface of the ER that contains 
ribosomes forms a rough structure and is hence called rough endoplasmic reticulum 
(RER). It is the major site of protein synthesis. The ER with a surface without 
ribosomes is called smooth endoplasmic reticulum (SER). Here, synthesis of sterols 
and lipids take place and it stores calcium ions. Based on its location inside the cell, 
ER can be further categorized into perinuclear ER that surrounds the nuclear envelope 
and cortical ER, which is present underneath the plasma membrane.  
1.2.1. Protein translocation at the ER 
Proteins that are to be secreted or inserted into organelles such as ER lumen and 
plasma membrane are transported across the ER. It is predicted that up to one-third 
of eukaryotic proteins are passing through the endoplasmic reticulum (Aviram et al. 
2016). Since mRNAs are made in the nucleus, they must be exported out of the 
nucleus in order to be translated by ribosomes to make proteins and targeted to their 
destination. The targeting of these proteins targeting can be either be co-translational 
or post-translational targeting. 
1.2.1.1. Co-translational translocation to the ER 
Targeting of mRNAs to the ER during translation is achieved by signal recognition 
particle (SRP) and the signal receptor (SR), which is embedded in the ER membrane 
and recognizes SRP (Waters and Blobel 1986). Both are highly conserved among all 
the kingdoms (Keenan et al. 2001, Zimmermann et al. 2010).  
The delivery of newly synthesized secretion or membrane proteins is a very crucial 
step because the hydrophobic regions in nascent peptides could be exposed to the 
aqueous environment in the cytoplasm and thus lead to protein aggregation. Co-
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translational targeting of proteins can prevent this problem and make safe delivery to 
their destinations. 
The co-translational delivery of proteins starts with the signal sequence of the newly 
synthesized peptides that are recognized by the SRP. The SRP binds to the nascent 
peptide via the S domain as soon as the hydrophobic transmembrane domains (TMD) 
exits from the ribosomes (Wild et al. 2004 and Reithinger 2013). Simultaneously, the 
Alu domain of SRP interacts with ribosomes at the elongation factor binding site and 
slows down the speed of ribosome elongation (Figure 3). The complex of ribosome-
nascent chain-SRP is then targeted to the ER membrane by the interaction of the S 
domain of the SRPwith SR (SRα/SRβ) at the ER membrane. The whole complex is 
stabilized on the ER membrane by binding to GTP. Once the complex is ready to insert 
or translocate the nascent peptide, the SRP and SR hydrolyze their bound GTP and 
release from the complex for the next round of co-translational targeting (Figure 3).   
There are several heat shock proteins that support nascent polypeptides in order to 
not misfold. For example, in yeast, the absence of SRP can lead to a reduction of 
protein synthesis and induction of heat shock proteins (Hsp70p) to prevent 
aggregation of these proteins or help them to fold correctly and target their destination 
via SRP-independent pathway (Hann and Walter 1991).     
1.2.1.2. Post-translational translocation to the ER 
In the post-translational targeting pathway, the proteins are fully synthesized in the 
cytoplasm and subsequently targeted to the ER. Computational analysis in yeast for 
the secretion proteome from Ast et al. (2013) revealed that up to 43.3% of proteins are 
predicted to be targeted independently of SRP. Since SRP recognizes the TMDs of a 
nascent peptide, which needs to be at least 70-80 amino acid residues, peptides with 
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Figure 3. Cartoon representation of SRP-dependent co-translational translocation at the ER. 
In the cytosol when the ribosomes translate N-terminal TMD of the nascent peptide, the SRP 
particle binds to the TMD. The stability of complex during targeting is achieved by the presence 
of GTP. At the ER membrane, SR receptors (SRα/SRβ) which are located close to the 
Sec61 translocon complex receives the SRP bound ribosomes and initiates the 
translocation across the ER membrane. After the insertion of targeting peptide, the hydrolysis 
of GTP leads to the release of SRP from the complex and available for the next round of 
ribosomes targeting. Figure adapted from Eichler and Moll (2001).    
 
shorter sequences cannot be recruited by SRP for targeting to the ER (Ast and 
Schuldiner 2013; Ast et al. 2013). Also, the tail-anchored (TA) proteins whose TMDs 
are present at the C-terminus cannot recruit SRP and are targeted post-
translationally.  
In yeast, the Guided Entry of TA proteins (GET) pathway was proposed as a delivery 
system for TA proteins to the ER (Schuldiner et al. 2008). GET is also conserved in 
mammalians and called here the TRC40 pathway (Stefanovic and Hegde 2007). The 
TA proteins have TMDs with at least 40 amino acid residues at the C-terminus (Shao 
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and Hedge 2011). As the ribosome completes the translation of the TA proteins, Sgt2p 
(small glutamine-rich-peptide repeat (TPR)) is the first protein that binds to the nascent 
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
Figure 4. Cartoon representation of the GET pathway for post-translational translocation. As 
the C-terminal TMD (purple) of TA proteins is synthesized by the ribosomes, the Stg2p 
recognizes this TMD and binds to form a pre-targeting complex. The Get3p in yeast 
recognizes this complex and targets them to the ER membrane where the Get1-Get2 complex 
received this cargo and proceeds for the translocation of peptides across the ER membrane. 
The figure and the text are adapted from Puyenbroeck and Vermeire (2018). 
TA protein and prevents it from aggregation (Figure 4) (Wang et al. 2010). The Get3 
protein, which is a 40kDa ATPase can form a dimer and can create a groove-like 
structure with open and closed conformation states (Favaloro et al. 2008, Schuldiner 
et al. 2008, Stefanovic and Hegde 2007). When Get3 is in an open conformation, it 
can interact with the Stg2p-TA protein complex and recruit it to the ER membrane 
where it is received by the Get1-Get2 complex. Get3 then releases the TA proteins by 
ATP hydrolysis (Hu et al. 2009, Schuldiner et al. 2008). There are other pathways of 
protein delivery to the ER such as translocation of proteins via the Sec61 translocon 
with the auxiliary essential Sec62-Sec63 and non-essential Sec66 and Sec72 
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components of ER membrane which can be also targeted co-translationally but in 
SRP-independent manner (Deshaies and Schekman 1987and 1989, Rothblatt et al. 
1989, Sadler et al. 1989) in yeast. In this SRP-independent pathway, the newly 
synthesized proteins in the cytoplasm are recognized by chaperone proteins like 
Hsp70 or Hsp90 that target them to the ER membrane. As the complex reaches the 
ER membrane, the signal sequence (SS) in these proteins is recognized by Sec61 
translocon and the chaperone proteins are now released from the complex (Plath and 
Rapoport 2000). Then, the segment of a targeted protein that has to be inserted into 
the ER membrane binds to the Kar2 protein through the J domain of the Sec61 
translocon in the lumen to ensure successful translocation of target protein across the 
ER (Brodsky and Schekman 1993, Sadler et al. 1989). 
1.2.1.3. Protein quality control (PQC) at the ER 
Each step in the delivery of proteins to the ER is critical for the cells. A mistake during 
translocation of proteins across the ER leads to misfolding or aggregation of proteins 
that could be toxic for the cells. Several neurological diseases such as Alzheimer’s 
and Parkinson’s have been linked to protein aggregation (Hetz et al. 2013). Stress 
generated by the accumulation of misfolded proteins in the ER is called ‘ER stress’. 
This can be because of oxygen stress (hypoxia), nutrient deprivation or abnormal 
levels of calcium. To ensure a balance between the protein-folding capacity and 
protein-folding demands, cells keep track of the levels of misfolded proteins (Hetz and 
Papa 2017). As the accumulation of misfolded proteins increases, an intracellular 
response mechanism in cells kicks in to restore ER homeostasis. This so called 
Unfolded Protein Response (UPR) can stop the production of misfolded proteins, 
increase the production of ER chaperones to help proteins to refold correctly, initiate 
apoptosis in case of the severe load of misfolded proteins in the ER, and re-translocate 
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wrongly folded proteins back to the cytoplasm for their degradation by proteasomes 
in  the ER-associated Degradation (ERAD) pathway (Hetz and Papa 2017).  
1.2.1.3.1. The Unfolded Protein Response 
In yeast, misfolding of proteins is monitored by a 126 kDa ER transmembrane sensor 
protein called Ire1p (Cox and Walter 1996, Mori et al. 1993). It is highly conserved  
 
 
  
  
  
  
 
 
 
 
 
 
 
 
 
Figure 5. Activation of S.cerevisiae Ire1p upon ER stress to induce the UPR. Once activated, 
Ire1p changes its confirmation by trans-autophosphorylation and oligomerization, which leads 
to splicing of HAC1 pre-mRNA. The ribosomes translate the spliced HAC1 to produce Hac1p 
that induces expression of downstream genes involved in the UPR pathway. The figure and 
the text are adapted from Wu et al. (2014). 
among eukaryotes. Ire1p is activated by binding directly to misfolded proteins in the 
ER lumen (Figure 5). The cytosolic part of Ire1p has two functional domains with 
kinase and RNAse activities. As soon as the Ire1p is activated, it undergoes 
conformational changes by oligomerization followed by trans-autophosphorylation via 
its cytosolic kinase domain. Once Ire1 is in an active conformation, the RNAse of Ire1 
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cleaves the intron of the HAC1 pre-mRNA. The spliced HAC1 mRNA is translated by 
the cytosolic ribosomes to produce Hac1 protein (Figure 5). Hac1p acts as a 
transcription factor for many genes of the UPR pathway (nearly 400 genes, belongs 
to ER chaperone, lipid biosynthesis, and ERAD) and induces their gene expression to 
fully restore ER homeostasis.  
1.2.1.3.1.1. The ER-associated Degradation (ERAD) pathway 
When the levels of misfolded proteins increase, it is also necessary to degrade these 
proteins before they become unhealthy for the cells. To degrade misfolded ER or 
membrane proteins they need to be re-translocated to the cytoplasm by the so-called 
ERAD pathway (Baldridge and Rapoport 2016). Genetic and biochemical studies in 
budding yeast and mammalian systems led to the identification of the components of 
the ERAD pathway and an E3 ubiquitin ligase complex as its core component 
(Bordallo et al. 1998, Bays et al. 2001, Ruggiano et al. 2014). The ubiquitin system is 
a process of attachment of a small protein of 76 amino acid residues called ubiquitin 
to the misfolded protein and is composed of three steps process. These steps include 
the activating proteins called E1, the conjugating proteins called E2 and the ligases 
involved in the degradation called E3 (Pickart 2001).  
In yeast, substrate recognition by the E3 ligase system is based on the location of 
misfolded proteins (ER lumen or cytosolic side of ER). Two models have been 
proposed: 1.) ERAD-C substrates in the ER lumen are degraded via the Doa10 
complex, whereas 2.) ERAD-M substrates on the cytosolic side of the ER are 
degraded via the Hrd1 complex (Taxis et al. 2003, Vashist and Ng 2004, Carvalho et 
al. 2006). In the mammalian system most studied, E3 ligases are Hrd1 and Gp78 
which are homologous to yeast but targets different kinds of substrate (Christianson 
et al. 2011 and Zhang et al. 2015).  
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 The Doa10 complex contains Cue1-Ubc7 as a core complex with Cdc48, Npl4, Ufd1, 
Ubx2 as cofactors, whereas the Hrd1 consists of Hrd3, Der1, Yos9, Kar2 and Usa1 as 
cofactors (Figure 6).  
    ERAD-C                                            ERAD-L                                ERAD-M
 
        Doa10 complex                                             Hrd1 complex 
Figure 6. Three categories of the ERAD pathway in S.cerevisiae. A cartoon figure showing 
three different substrates for degradation by ERAD along with their core components and co-
factors of the Doa10 complex and Hrd1 complex. The red-colored star indicates the misfolded 
domain of the nascent peptide. The ERAD is categorized into three categories based on the 
recognition of the location of its substrates as; ERAD-C (cytoplasmic side of the ER), ERAD-
L (in the ER lumen) whereas ERAD-M (across the membrane of the ER). The ERAD-L and 
ERAD-M is processed by the Hrd1 complex and ERAD-C are processed by the Doa10 
complex. The figure and text are adapted from the Ruggiano et al. (2014). 
 
The Der1 protein dislocates the misfolded protein from the luminal part of the Sec61p 
translocon. Yos9p, together with Hrd3p and Kar2p then recognizes the polypeptides 
that are needed to be degraded by the ubiquitin ligase Hrd1p. Then, Hrd1p together 
with Hrd3p binds directly to initiate their degradation and called as ERAD-L pathway 
(Figure 6) (Plemper et al. 1997, Bhamidipati et al. 2005, Kim et al. 2005, Szathmary 
et al. 2005, Carvalho et al. 2006, Denic et al. 2006). The proteins of the ER membrane 
that are needed to be degraded via ERAD-M are also transported back to the cytosol 
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by the Hrd1/Hrd3 complex, but the factors involved in this process still remain elusive 
(Rugginao et al. 2014).  
The Doa10 complex of ERAD-L is dedicated to the degradation of peptides that are 
on the cytosolic face of the ER (Huyer et al. 2004, Vashist and Ng 2004, Nakatsukasa 
et al. 2008). The Doa10 complex localizes to the ER and to the inner nuclear 
membrane (Swanson et al. 2001, Deng and Hochstrasser, 2006). The chaperone 
proteins that mediate this process are Hsp70p and Hsp40p, which recognizes the 
ubiquitin of the peptides that are needed to be degraded by Doa10 complex 
(Nakatsukasa et al. 2008). 
1.3. Brefeldin A resistance factor 1 protein (Bfr1p): An unconventional RBP 
proposed to play roles in the secretion pathway, ploidy control, and translation. 
Brefeldin A (BFA) is an inhibitor of protein transport between the ER and Golgi 
apparatus. In yeast, deletion of ERG6 leads to increased cell permeability and 
sensitivity to BFA. BFR1 was first reported as a multi-copy suppressor of BFA induced 
lethality in S.cerevisiae (Jackson and Képès 1994).  BFR1 is a non-essential gene and 
cells deleted for BFR1 (bfr1Δ) are viable but show cell shape alterations, increased 
cell size and defects in nuclear segregation (Jackson and Képès 1994). Furthermore, 
deletion of BFR1 leads diploid cells to produce an ascus containing asci instead of 
spores (Xue et al. 1996). Two-hybrid interaction studies suggest that Bfr1p interacts 
with Bbp1p and proposed to play a role in cell cycle regulation (Xue et al. 1996). Bbp1p 
is a component of the spindle pole body (SPB) and together with the nuclear envelope 
protein Mps2p, Bbp1p controls the PB duplication (Schramm et al. 2000). Additionally, 
Bfr1p associates with the SESA (Sym2p-Eap1p-Scp160p-Asc1p) network via mRNAs 
(e.g. POM34 mRNA) and inhibits its translation to regulate the SPB duplication 
(Senzen et al. 2009). Interestingly, Bfr1p only co-immunoprecipitated with the 
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Scp160p and Asc1p but not with the Sym2p and Eap1p of SESA network suggesting, 
Bfr1p interaction with SESA is possibly via Br1p-Bbp1p interactions and thus 
implicated in chromosomal mis-segregation and change of ploidy.  
BFR1 encodes for a 55 kDa protein that contains three coiled-coil domains covering 
amino acids 17-178, 237-281, and 398-469 (Results, Figure 2.3 A). Bfr1p localizes 
predominantly to the endoplasmic reticulum (ER) but also shuttles between ER and 
cytoplasm (Lang et al. 2001). Furthermore, Bfr1p co-purifies with polysome complexes 
together with the RBP Scp160p. The interaction between Bfr1p and polysomes is 
dependent on RNA (Lang et al. 2001). Although Bfr1p does not contain canonical 
RNA-binding domains, Bfr1p binds to several hundreds of mRNAs that encode for 
endomembrane proteins or secretion proteins, but also binds to mRNAs encodes for 
ribosome biogenesis, ncRNA processing, protein glycosylation and glycoprotein 
biosynthesis (Hogan et al. 2008, Lapointe et al. 2015). Bfr1p binds to these mRNAs 
during translation at the ER (Lapointe et al. 2015) and PAR-CLIP data of Bfr1p-RNA 
interactions revealed that there are at least six residues in Bfr1p that cross-link to and 
therefore directly contact RNA (Kramer et al. 2014). These six residues (R38, H79, 
K138, F211, Y225, and F239) are found in the first two coiled-coil domains of Bfr1p 
suggesting these two domains are important for the RNA-binding functions of Bfr1 
protein.  
During cellular stress, the translation of mRNAs is repressed, and these mRNAs are 
localized to a membrane-less compartment in the cytoplasm known as processing 
bodies (P-bodies). P-bodies are formed by phase separation and store mRNAs and 
its degradation machinery components to regulate mRNA turnover. Bfr1p was shown 
to be a part of the P-bodies component and targets some mRNAs (eg. RPS16A) during 
late-phase of P-bodies formation when cells are stressed for extended periods of 
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glucose starvation (Simpson et al. 2014). Under normal growth conditions, Bfr1p 
together with Scp160p is proposed to protect mRNAs by blocking their access by P-
body components (Weidner et. 2014).     
Bfr1p has also proposed as a checkpoint for the UPR activation during elevated ER 
stress (Low et al. 2014). It was shown that the Bfr1 down-regulate the UPR and 
secretion pathway when a novel group of kinetochore genes (CFT19 complex) is 
deleted (Low et al. 2014).  
Taken together, Bfr1p binds RNA and loss of BFR1 affects secretion pathway, ploidy 
maintenance, assembly of P-bodies.  
1.4. Functional similarities between Bfr1p and Scp160p. 
Scp160p (Saccharomyces cerevisiae protein involved in the control of ploidy) is a 160 
kDa protein with 14 repeats of the highly conserved hnRNP K-homology (KH) domains 
and the yeast member of the vigilin protein family (Weber et al. 1997, Lang and 
Fridovich-Keil 2000, Cheng and Jansen 2017). Several studies have proposed that 
Scp160p and Bfr1p share functional similarities (Lang and Fridovich-Keil 2000, 
Senzen et al. 2009). The deletion of either SCP160 or BFR1 has similar consequences 
such as abnormal cell shape and cell size, issues with maintenance of ploidy 
suggesting that both proteins either function together and dependent on each other.  
A microarray analysis from Hogan et al. (2008) showed that the mRNA interactome of 
Scp160p and Bfr1p overlap in terms of mRNA partners. In addition, Scp160p interacts 
with polysomes via Bfr1p and, in contrast to Bfr1p, in an RNA-dependent manner 
(Lang et al. 2001). Similarly, our lab has previously shown that Scp160p acts as a 
translational enhancer of a set of mRNAs by efficient recycling of tRNAs and 
preventing their diffusion (Hirschmann et al. 2014).  
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Also, studies have shown that under normal growth conditions, Bfr1p together with 
Scp160p prevents P-bodies formation by inhibiting access to the P-bodies 
components since the deletion of either BFR1 or SCP160 was shown to induce the 
formation of P-bodies (Weidner et al. 2014). This suggests that Bfr1p might also play 
a role in translation similar way as Scp160p since these two proteins bind to similar 
mRNAs during translation and share a similar set of functionalities.  
1.5. Aims of this study 
Since the first identification of Bfr1p in 1994, multiple functions have been proposed 
for Bfr1p, such as a multi-copy suppressor of brefeldin A exposure, roles in secretion, 
nuclear segregation, and RNA-binding. However, the function of Bfr1p at the molecular 
level remains unclear, especially since all the previous studies have been performed 
with the BFR1 deletion (bfr1Δ) cells and have not excluded secondary effects resulting 
e.g. from nuclear mis-segregation.  
Therefore, the present study focuses on two aspects; 
1. The functional relationship between the RNA-binding function of Bfr1p 
and the phenotypes associated with loss of BFR1. As a starting point, I 
created point mutations in the residues of Bfr1p that have been shown to UV-
cross link with the RNA and investigated whether the loss of RNA-binding 
affects the known phenotypes such as cell ploidy, BFA resistance, and P-
bodies induction. 
2. The function of Bfr1p in translational control of its mRNA targets and in 
protein translocation of the encoded proteins. From the previously 
published high-throughput studies of Bfr1p-mRNA complexes, I characterized 
two RNA binding partners (ERG4 and OSH7) via ribosome affinity purifications 
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and polysome profiling approaches to find how Bfr1p affects the translation of 
these mRNAs at the ER. 
Results 
 
20 
 
2. Results 
2.1. The RNA-binding function of Bfr1p is important for its localization to the ER. 
2.1.1. K138 and F239 residues of Bfr1p are highly conserved among 
ascomycetes. 
Bfr1p has three coiled-coil domains but does not have any canonical RNA-binding 
domains. However, from previous studies (Hogan et al. 2008, Kramer et al. 2014, 
Laponite et al. 2014) it has been shown that Bfr1p binds to several hundreds of 
mRNAs. In vivo UV-crosslinking of Bfr1p with mRNAs revealed six crosslink sites 
(Kramer et al. 2014) that span within first two coiled-coil domains. To check whether 
these six residues are conserved in the phylum Ascomycota of the fungal kingdom, I 
performed a multiple sequence alignment. Among these six RNA-binding residues of 
Bfr1p (R38, H79, K138, F211, Y225 and F239), I found that K138, Y225 and F239 are 
highly conserved among ascomycetes for at least 8 species (Figure 2.1), and when 
compared to more than 10 species K138 and F239 remains highly conserved. 
However, all the six residues of Bfr1p are conserved and thus, I decided to mutate 
these residues to further characterize the Bfr1p interaction with mRNAs. 
2.1.2. RNA-dependent localization of Bfr1p to the ER. 
To confirm whether localization of Bfr1p to the ER is RNA-dependent, I constructed a 
yeast strain expressing Bfr1p with a yeast enhanced GFP (yeGFP) tag fused at the C-
terminus (Bfr1p-yeGFP) and treated the lysates with RNase. The cytosolic and 
membrane fractions were separated by subcellular fractionation and proteins were 
detected by western blot. Lysates without RNase treatment were used as a negative 
control.  
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Figure 2.1. Multiple-sequence alignment of Bfr1p from various fungi reveals K138 and F239 
RNA-binding residues are highly conserved. Alignment of Bfr1p was performed for 8 different 
species of the fungal kingdom with Clustal Omega (EMBL-EBI). The output file was prepared 
with ESprint 3 and manually edited for residues 1-291 of Bfr1p. UV cross-linked RNA-binding 
residues of Bfr1p are highlighted in yellow with arrows. 
The western blots revealed that a majority of the Bfr1p co-fractionated with the 
membrane fraction only in lysates that are not treated with RNase, whereas a reduced 
Bfr1p level is observed in the membrane fraction after treatment with RNase (Figure 
2.2). However, Bfr1p can still be detected in the membrane fraction after RNase 
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treatment. The distribution of cytoplasmic fraction and membrane fractions were 
controlled using Pgk1p and Sec61p as a cytoplasmic and membrane marker, 
respectively.  
  
  
 
 
 
Figure 2.2. Bfr1p localize to the ER in RNA-dependent manner. Bfr1p redistributes between 
the membrane and cytosolic fractions upon RNAse treatment. (M6) membrane fraction (pellet 
from 6000g), (M18) membrane fraction (pellet from 18,000g), and (C) cytoplasmic fraction 
(supernatant from 18,000g). Pgk1p and Sec61p serves as a marker for cytoplasmic and 
membrane fractions respectively. 
2.1.3. Mutating F239 alone or all the six RNA-binding residues to alanine results 
in the loss of Bfr1p localization to the ER.  
After establishing RNA-dependent localization of Bfr1p to the ER, I next wanted to 
establish if all six RNA-binding residues of Bfr1p are important for its localization. To 
answer this, I generated strains with mutations in RNA-binding residues of Bfr1p-
yeGFP either by creating single point mutations of these residues or mutating all six 
together by replacing them with alanine residues (see Methods and Figure 2.3 A). 
Since it has been shown that all six cross linked residues are within first two coiled 
domains, I also generated a strain with a truncation of third coiled domain (Bfr1p(1-
397)) to find out whether the first two coiled-coil domains are sufficient for the function 
of Bfr1p. Western blots and their quantification revealed that the expression of Bfr1p 
is not affected by either mutating the RNA-binding residues or truncating the third 
coiled-coil domain when compared to the wild type full length Bfr1p (Figure 2.3 B, 
C). Since the expression of Bfr1p mutants was not altered by exchanging their RNA- 
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Figure 2.3. Mutations in RNA-binding residues of Bfr1p do not affects its expression. A. 
schematic view of the genomic BFR1 locus. RNA-binding residues R38, H79, K138, F211, 
Y225, and F239 were replaced with alanine and cloned into a plasmid. The mutant bfr1mut6A 
contains all six mutations, Bfr1p(1–397) is a truncation lacking the third coiled-coil were 
introduced in genome. B. Westen blot of expression of Bfr1p constructs shows no change in 
the protein expression levels. Pgk1p served as a control for normalization of loading and 
untagged wild strain as a control for GFP antibody specificity. C. Quantification graph 
displayed as % protein levels of Bfr1p constructs normalized to Pgk1p levels from three 
biological replicates. Error bars show ±SD. 
binding residues, I performed fluorescence microscopy analysis to find whether these 
mutations impact Bfr1p localization the ER. As suspected, I found that mutations in 
the highly conserved residue F239A alone or in all six RNA-binding residues, affects 
Bfr1p localization to the ER when compared to the wild type protein (Figure 2.4A). 
Interestingly, Bfr1p with a truncation of the third coiled-coil domain and all the other 
individual mutations (R38A, H79A, K138A, F211A, Y225A) shows normal localization 
to the ER. (Figure 2.4B). To further validate our results, I performed subcellular 
fractionation with strains expressing wild type full length Bfr1p, Bfr1p(1-397) and 
bfr1mut6A. Western blots from subcellular fractionations revealed similar results as  
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Figure 2.4. RNA-binding mutants affects ER localization of Bfr1p. A. and B. Intracellular 
distribution of yeGFP-tagged Bfr1p constructs. Plasmid-expressed HDEL-DsRed serves as 
an ER marker. Bfr1p variants of mutants bfr1mutF239A and bfr1mut6A show loss of 
colocalization between Bfr1p and the ER. None of individual mutants including Bfr1p(1-397) 
affect the distribution of Bfr1p. Scale bar, 8 μm. C. Distribution of Bfr1p constructs in 
subcellular fractionation. (I) input, (M) membrane fraction (pellet from 18,000g), (C) 
cytoplasmic fraction (supernatant from 18,000g). Pgk1p serves as cytosolic and Sec61p as 
ER markers. D. Quantification of subcellular fractionation of yeGFP-tagged Bfr1p constructs. 
Data are displayed as relative protein levels. Protein in the membrane fraction was normalized 
to Sec61p and in cytoplasmic fraction to Pgk1p. Results stem from three biological replicates. 
Error bars show ±SD. 
observed with microscopy as Bfr1p shifts from membrane to the cytoplasmic fraction 
in bfr1mut6A (Figure 2.4C). Quantification from subcellular fractions of three biological 
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replicates confirms the observation when normalizing against Pgk1p or Sec61p for 
cytoplasmic and membrane fractions, respectively (Figure 2.4D). These data suggest 
that RNA-binding residues are important for Bfr1p to localize at the ER.  
2.2. The known phenotypes of bfr1Δ are independent of its RNA interaction.  
2.2.1. The RNA-binding mutants of Bfr1p does not induce P-bodies. 
It has been shown in previous studies that loss of BFR1 (bfr1Δ) induces P-bodies 
under normal growth conditions (Weidner et al. 2014) and that Bfr1p targets certain 
mRNAs to P-bodies during late phase of glucose stress (Simpson et al. 2014).  
  
 
 
Figure 2.5. The RNA-binding mutants of Bfr1p does not induce P-bodies. Premature P-bodies 
are not induced by RNA-binding mutations of Bfr1p. Images were collected from 
logarithmically growing cells shifted for 30 minutes to media with or without glucose to induce 
P-bodies. Edc3p-mCherry serves as P-body marker. Unlike a BFR1 deletion, neither RNA-
binding mutations nor Bfr1p(1-397) show any P-body foci in cells growing in glucose-
containing medium. Scale bar, 5 μm. 
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Therefore, I wanted to check whether the mutations in the RNA-binding residues of 
Bfr1p also induce P-body formation. To answer this, I performed fluorescence 
microscopy of cells growing in log phase that were shifted to medium lacking glucose 
for 30 minutes to induce P-body formation before proceeding to live cell imaging. Cells 
co-expressed Edc3p-mCherry that served as a P-bodies marker (Weidner et al. 2014). 
None of the RNA-binding mutant constructs nor the truncation of third coiled-coil 
domain of Bfr1p shows premature induction of P-bodies under normal conditions 
(Figure 2.5, left panel). This suggests that the increase in P-bodies from bfr1Δ is 
possibly due to a loss of its interaction with other proteins and, thus is independent 
from the RNAs interaction of Bfr1p. 
2.2.2. The RNA-binding mutants of Bfr1p does not alter cell ploidy. 
One of the first reported phenotypes of loss of BFR1 were changes in cell shape and 
size as well as an increase in DNA content (Jackson and Képès 1994). Flow-cytometry 
(FACS) analysis showed that the bfr1Δ cells turn from haploid to diploid or tetraploid 
cells and was later attributed to defects in nuclear segregation and nuclear spindle 
formation (Xue et al. 1996). Since these experiments were performed in bfr1Δ cells it 
remained unclear if RNA interactions of Bfr1p contribute to regulating the cell ploidy. 
To investigate this, I performed FACS analysis of the cells with mutations in RNA-
binding residues of Bfr1p. Wild type haploid and diploid cells were used as a reference 
for this experiment. As previously shown, FACS histograms of bfr1Δ cells show peaks 
at 2C/4C (i.e. 2N to 4N cells) like wild type diploid cells whereas haploid wild type 
Bfr1p1 expressing cells show 1C/2C peaks (1N to 2N) like wild type haploid cells 
(Figure 2.6). Interestingly, I did not find any change in ploidy for the cells with Bfr1p 
mutation constructs including truncation of third-coiled coil domain and all these 
constructs show 1C/2C condition like wild type Bfr1p. However, a small percentage of 
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cells (4-6 %) in bfr1mut6A show 2C/4C conditions. From this data I conclude that the 
Bfr1p can possibly have multiple roles and RNA-binding function of Bfr1p is 
independent from the ploidy of the cells. 
  
  
 
 
 
 
 
 
 
 
 
Figure 2.6. The ploidy phenotype of Bfr1p is not affected by RNA-binding mutants. Flow 
cytometry analysis of Bfr1p variants showing that ploidy is not changed by the mutations in 
RNA-binding residues of Bfr1p. Histograms show plots of DNA content after propidium iodide 
staining. 
2.2.3. The RNA-binding mutants of Bfr1p are not sensitive to Brefeldin A. 
Yeast cells that have lost the Erg6 protein (erg6Δ) are highly sensitive to the drug 
brefeldin A (Graham et al. 1993 and Vogel et al. 1993). Erg6p is an enzyme that 
functions as a catalyst in the biosynthesis of zymosterol. Normally, brefeldin A cannot 
enter yeast cells due to their low permeability for this drug. The loss of ERG6 alters 
the sterol composition and increase permeabilization of brefeldin A. BFR1 was 
originally reported as a multi-copy suppressor of brefeldin A sensitivity (Jackson and 
Képès 1994) and proposed to have a role in secretion. I wanted to find out whether 
the high-copy suppression of brefeldin A sensitivity is achieved via its interactions with 
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RNA, especially since the protein co-localizes with ER, the site of membrane protein 
synthesis. Therefore, I expressed RNA-binding mutants of Bfr1p in 2 µm plasmids  
 
  
 
 
 
 
 
Figure 2.7. Brefeldin A sensitivity of erg6Δ is rescued by overexpression of wild-type Bfr1p 
and RNA-binding mutants. Bfr1p mutants (bfr1mut5A: R38A, K138A, F211A, Y225A, F239A; 
bfr1mut4A: R38A, K138A, F211A, F239A; bfr1mut3A: R38A, K138A, F239; bfr1mut2A: 
K138A, F239A) were expressed from YEplac181 (LEU2) plasmids in double knockout erg6Δ 
bfr1Δ cells. Wild type and erg6Δ cells with empty YEplac181 plasmids served as controls. 
Logarithmically growing cells were serially diluted and plated on dropout (-leucine) agar with 
or without 50 µg/ml brefeldin A (BFA), and grown for 72 h at 30 °C. 
(YEplac181) in erg6Δ bfr1Δ double knockout cells and treated with or without 50 µg/ml 
brefeldin A. As previously reported, I could show that erg6Δ cells do not grow on media 
with 50 µg/mL of brefeldin A and that overexpression of the wild type Bfr1p rescues 
brefeldin A sensitivity in erg6Δ bfr1Δ double knockout cells (Figure 2.7). Surprisingly, 
all mutant constructs rescue cells from brefeldin A like wild type Bfr1p. Therefore, I 
conclude that RNA-binding function of Bfr1p is independent from its role in secretion. 
2.3. Bfr1p interacts with ERG4 mRNA via its known RNA-binding residues. 
Recent studies on Bfr1p showed that it binds to several hundreds of mRNAs that are 
translated at the ER (Hogan et al. 2008, Mitchell et al. 2013, Lapointe et al. 2015). 
These mRNAs encode for proteins of the endomembrane system or secreted proteins 
(Lapointe et al. 2015). Bfr1p was also reported as a component of polysomes and has 
a potential role in translation of mRNAs (Lang et al. 2001). Therefore, I wanted to 
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address the physiological impact on these mRNAs of mutations in RNA-binding 
residues of Bfr1p. Based on previous studies (Hogan et al. 2008 and Lapointe et al. 
2015) I selected mRNAs that were significantly enriched as bound by Bfr1p and whose 
encoded proteins are linked to known phenotypes of bfr1Δ or Bfr1p overexpression. 
From this list I chose five mRNAs encoding ER or Golgi proteins (IMH1, RUD3, 
SGM1), proteins involved in ER-Golgi transport (IMH1) or involved in sterol 
biosynthesis (ERG4), and sterol binding (OSH7) as targets of Bfr1p and characterized 
them further. 
2.3.1. Loss of BFR1 does not affect target mRNA levels.   
Since these five mRNAs have been shown to bind Bfr1p, I wanted to verify whether in 
bfr1Δ, Bfr1p(1-397), and bfr1mut6A mutants their stability is affected compared to the 
wild type cells. Therefore, I extracted total RNA from logarithmically growing cells 
(three replicates) and quantified these mRNAs by qRT-PCR. Normalized (to ACT1) 
levels of target mRNAs revealed that none of the mRNAs demonstrated significant 
changes in their levels when compared to the wild type cells (Figure 2.8). Hence, I 
conclude that Bfr1p does not influence the stability of these mRNAs. 
  
 
 
 
 
 
 
Figure 2.8. Stability of mRNAs does not change upon loss of BFR1. Quantification of mRNA 
levels of IMH1, RUD3, ERG4, OSH7, and SGM1 by qRT-PCR in wild type, bfr1Δ, Bfr1p(1-
397) and bfr1mut6A cells. Data are presented as mean values from three independent 
experiments with ±SD. 
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2.3.2. Mutating the RNA contact sites in Bfr1p reduces its interaction with ERG4.  
Although, the levels of target mRNAs were unaffected in the Bfr1p mutants or in bfr1Δ 
(Figure 2.8), I wanted to test whether the interaction of these mRNAs with Bfr1p 
depends on the known RNA-binding residues. Using the Bfr1p constructs fused to 
yeGFP, I co-immunoprecipitated these mRNAs with Bfr1p wild-type, bfr1mut6A and 
Bfr1p(1-397) using anti-GFP nanobody-coupled magnetic beads (GFP-MA trap, 
Chromotek) and quantified them by qRT-PCR. The wild-type strain (mock) served as 
the negative control and MID2 mRNA (an mRNA that binds to the RBP Khd1p (Syed 
et al. 2018)) served as a non-target control mRNA in the immunoprecipitation. The fold 
enrichment of immunoprecipitated fractions revealed that only ERG4 mRNA shows 
significant binding to full length wild type Bfr1p (Bfr1p FL) compared to MID2 mRNA 
(Figure 2.9).  
  
  
 
 
 
 
 
 
 
Figure 2.9.  ERG4 mRNA binding to Bfr1p is affected by mutating its RNA-binding residues. 
RNA binding of full-length Bfr1p (FL wild type), Bfr1p(1–397), and bfr1mut6A is assessed by 
coimmunoprecipitation of ERG4 and OSH7 mRNAs and qRT-PCR. MID2 mRNA serves as a 
non-target for Bfr1p. Data are presented as mean values from three biological and two 
technical replicates, each with ±SD. 
As expected, the RNA-binding mutant version bfr1mut6A strongly reduces this binding 
confirming that the ERG4 mRNA directly interacts with Bfr1p. OSH7 mRNA is more 
enriched in Khd1p immunoprecipitations  than in those of Bfr1p, suggesting it to be a 
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potential target of Khd1p. Truncated Bfr1p(1-397) binds to ERG4 mRNA similar to 
wild-type. This confirms that the first two coiled-coils of Bfr1p with their important RNA-
binding residues are enough for the interaction with target mRNAs. Taken together, 
these results confirm that the ERG4 mRNA is a direct binder of Bfr1p and that the 
mutations in RNA-binding residues affects this binding. 
2.4. ERG4 mRNA localization to ER is independent of Bfr1p. 
In eukaryotes, mRNAs that encode membrane or secreted proteins are general co-
translationally targeted to the ER by SRP pathway (Walter et al. 1981, Görlich et al. 
1992). Previous studies from our and other labs show that mRNAs that are bound to 
RNA-binding proteins such as She2p (Schmid et al. 2006, Fundakowski et al. 2012) 
or Khd1p (Syed et al. 2018) can alternatively be targeted to the ER using these RNA-
binding proteins. Erg4p is predicted to have seven transmembrane domains and 
localizes to ER (Zweytick et al. 2000).  Since ERG4 mRNA binds directly to Bfr1p, I 
wanted to test whether the RBP Bfr1p plays any role in localization of ERG4 mRNA to 
ER. To follow ERG4 mRNA in vivo, I used a recently improved MS2-tagging system 
(Tutucci et al. 2017) and tagged ERG4 mRNA with 12 MS2 stem loops. The tagged 
mRNA was visualized by co-expressing a MS2 coat protein fused with GFP (MCP-
GFP). I used a fusion of the Scs2p transmembrane domain and 2x RFP (Loewen et 
al. 2007) to detect ER in this experiment. Consistent with the previous studies that 
have shown that ERG4 mRNA translates at the ER (Lapointe et al. 2015, Jan et al. 
2014),,  the majority of the wild type cells show ERG4 mRNA localization to the ER 
(86.6+/-3.6%) whereas, the loss of BFR1 has no significant impact on ER localization 
of ERG4 mRNA (84+/-2.6 %) when compared to wild type cells (Figure 2.10 A and 
B). Therefore, I conclude that Bfr1p has no role in targeting of ERG4 mRNA to the ER. 
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Figure 2.10. ERG4 mRNA localization to the ER is not dependent of Bfr1p. A. Representative 
images of cells expressing MS2-tagged ERG4 mRNA in wild-type and bfr1Δ. Scs2-TMD-2× 
RFP serves as an ER marker. White arrows indicate ERG4 mRNA particles. Scale bar, 8 μm. 
B. Quantification of ERG4 mRNA colocalization with ER in wild type and bfr1Δ. Data are 
presented as mean values from at least 100 cells from three biological replicates with ±SD. 
2.5. Erg4p expression and distribution is affected upon loss of BFR1. 
Since the localization of ERG4 mRNA to the ER does not depend on Bfr1p, I performed 
experiments to determine whether Bfr1p plays a role in the expression and localization 
of Erg4 protein at the ER. I generated a wild type, bfr1Δ and bfr1mut6A strains with 
Erg4p fused to yeGFP at the carboxy terminal end and performed fluorescence 
microscopy and western blot experiments to monitor the expression and localization. 
As previously published, I could see that in wild type, Erg4p predominantly localized 
at the ER (Zweytick et al. 2000) as gauged from expression of the ER marker 
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Figure 2.11. Erg4p expression is controlled by Bfr1p. A. Erg4p distribution changes upon 
deletion of BFR1. Representative images of cells from wild type, bfr1Δ, bfr1mut6A, bfr1Δ 
pep4Δ, and scp160Δ strains. HDEL-DsRed serves as an ER marker. Scale bar, 5 μm. B. 
Western blot showing down-regulation of Erg4p in bfr1Δ and bfr1mut6A compared to wild type. 
Total cell lysates were prepared from wild-type, bfr1Δ, and bfr1mut6A cells expressing a 
yeGFP-tagged Erg4p protein and Erg4p detected by an anti-GFP antibody. C. Erg4p shifts 
from ER to cytoplasm in bfr1Δ cells. Western blot following subcellular fractionation of wild-
type and bfr1Δ cells expressing yeGFP-tagged Erg4p. (I) input, (M) membrane fraction, pellet 
18,000g, and (C) cytoplasmic fraction, supernatant 18,000g. Pgk1p and Sec61p serve as a 
cytoplasmic or ER marker, respectively. 
HDEL-DsRed. Surprisingly, the expression of Erg4p in bfr1Δ cells was strongly 
reduced and a faint signal was observed all over the cell, including the cytoplasm 
(Figure 2.11 A, second row). However, expression and localization of Erg4p was 
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very similar to wild type levels in bfr1mut6A suggesting that Bfr1p but not its RNA-
binding residues are necessary for correct expression of Erg4p. Consistent with the 
microscopy data, a western blot of total cell lysates revealed that the Erg4p expression 
is strongly reduced in bfr1Δ (Figure 2.11 B). 
To test if the reduced Erg4p protein levels in bfr1Δ are due to increased vacuolar 
protein degradation, I generated a double knockout strain (pep4Δ bfr1Δ) expressing 
Erg4p fused to yeGFP. PEP4 encodes the major vacuolar proteinase A (Woolford et 
al. 1986), and loss of PEP4 should rescue Erg4p from degradation. However, Erg4p 
did not accumulate in the vacuole suggesting that the low levels of Erg4p is not due to 
targeting the protein to vacuolar degradation in bfr1Δ (Figure 2.11 A, lower panel). 
Although, ERG4 is a potential binder of Scp160p (Hogan et al. 2008), loss of SCP160 
does not affect the expression of Erg4p suggesting that this effect is specific for loss 
of Bfr1p. 
To investigate if the weaker and diffuse signals of Erg4p-yeGFP in bfr1Δ cells are due 
to improper localization to ER, I also performed subcellular fractionation from total cell 
lysates of wild type and bfr1Δ cells to separate membrane and cytoplasmic fractions 
and processed them for western blot. Consistent with our fluorescence microscopy 
data, I detected a strong reduction of the presence of Erg4p in bfr1Δ cells compared 
to wild type cells and an enrichment of Erg4p in cytoplasmic fractions was also seen 
(Figure 2.11 C). The separation of membrane and cytoplasmic fractions were judged 
by using Sec61p as membrane marker and Pgk1p as cytoplasmic markers.  
2.6. Loss of BFR1 promotes degradation of Erg4p at ER by the ERAD pathway. 
The ERAD (Endoplasmic Reticulum-Associated Degradation) pathway in cells targets 
misfolded proteins of the ER for degradation by 26S proteasomes in the cytoplasm. In 
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yeast, proteins that are misfolded during translocation at the ER membrane are first 
ubiquitylated by the ubiquitin-ligase Hrd1p, which facilitates their re-translocation to 
cytoplasm for degradation by the 26S proteasomes (Hampton 2002, Baldridge and 
Rapaport 2016). As we already know that the ERG4 mRNA is translated at the ER 
and that the localization of Erg4p in bfr1Δ cells shifts from membrane to cytoplasm, 
we hypothesized that loss of BFR1 possibly leads to misfolding of Erg4p, initiating its 
degradation by the ERAD pathway.  
To test our hypothesis, I generated a strain with a double deletion of BFR1 and HRD1 
(bfr1Δ hrd1Δ) and expressing Erg4p-yeGFP. To inhibit 26S proteasome activity, I used 
the inhibitor MG132 for our experiments (Liu et al. 2007). Cells were treated with 
cycloheximide (CHX, 100µg/ml) to arrest the translation and harvested at different time 
points (0 mins, 30 mins, 60 mins) to check amounts of Erg4p-yeGFP in bfr1Δ and 
bfr1Δ hrd1Δ. The loss of HRD1 should block the ubiquitination of misfolded Erg4p and  
 
 
 
 
 
 
Figure 2.12. Erg4p is degraded by ERAD pathway in absence of BFR1. Representative 
western blot showing accumulation of Erg4p in an ERAD mutant upon treatment with MG132. 
Total cell lysates were prepared from bfr1Δ and bfr1Δ hrd1Δ cells expressing yeGFP-tagged 
Erg4p. Cells were harvested at 0, 30, and 60 min after adding cycloheximide (CHX). Pgk1p 
served as a loading control. The asterisk indicates an unspecific band at 55 kDa detected by 
the GFP antibody. 
together with the inhibition of proteasomes should stabilize misfolded Erg4p. As 
expected, I can detect a small amount of Erg4p in bfr1Δ cells treated with MG132 
(Figure 2.12, lanes 4-6). In double knockout of bfr1Δ hrd1Δ cells a strong 
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accumulation of Erg4p was detected (Figure 2.12, last 3 lanes) which was further 
accumulated when proteasomes were blocked by MG132 from 0 mins to 60 mins. 
From this experiment, it was confirmed that the Erg4p is indeed misfolded during 
translocation at the ER in the absence of Bfr1p and eventually degraded by ERAD 
pathway. From our findings, I concluded that Bfr1p has a role in translation of ERG4 
mRNA at the ER and potentially in proper translocation of these proteins at the ER. 
2.7. Bfr1p regulates ERG4 translation at ER. 
Bfr1p binds to mRNAs that are translating at the ER and Bfr1p is a component of 
polysome complex. From our experiments it was evident that and Bfr1p plays a role in 
translational control of ERG4 mRNA. Our lab has previously shown that in yeast 
Scp160p also has a role in translation of a set of mRNAs by promoting efficient tRNA 
recycling during translation (Hirschmann et al. 2014). Therefore, I wanted to find out 
whether loss of BFR1 has any consequences on ERG4 translation at the ribosome 
level. To answer this, I performed a set of experiments to find either loss of BFR1 or 
the mutation in RNA-binding sites of Bfr1p is important for this regulation. 
2.7.1. Ribosomal occupancy on ERG4 is reduced upon loss of BFR1. 
Our lab has previously established Ribosome-affinity purifications (RAP) to analyse 
levels of ribosome occupancy on individual mRNAs (Hirschmann et al. 2014). 
Therefore, I decided to adopt this method to explore if loss of BFR1 changes 
occupancy of ribosomes on candidate mRNAs. The experiment was performed as 
described in (Hirschmann et al. 2014). In brief, I fused Rpl16a protein with a TAP-tag 
in wild type and bfr1Δ cells and arrested translation with CHX (100µg/ml) before 
harvesting the cells. The lysates were then subjected to immunoprecipitation to purify 
ribosomes together with RNAs. After degrading the ribosomal proteins from the 
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complex, RNAs were reverse transcribed and quantified by real-time PCR. The wild 
type and bfr1Δ strains untagged are served as control strains (mock) to detect 
unspecific immunoprecipitations.   
I tested ribosome occupancy for four different mRNA (ACT1, ERG4, OSH7 and MID2) 
in wild type and bfr1Δ. The ribosomal occupancy on ERG4 but not of ACT1 or MID2 
was significantly reduced in bfr1Δ compared to wild type cells (Figure 2.13). In 
contrast, no significant reduction was detectable for OSH7 suggesting that its 
translation might not be under Bfr1p control. Hence, I concluded that the loss of BFR1 
reduces ribosomes ERG4 mRNA during translation.   
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13. Loss of BFR1 reduces the ribosomal occupancy on ERG4 mRNA. Ribosome 
affinity purification (RAP) followed by qRT-PCR was performed to measure the ribosome 
association of ACT1, ERG4, OSH7, and MID2 mRNAs in wild-type and bfr1Δ cells. An 
untagged (mock) strain was used to normalize the data. Quantification graphs show 
percentage of occupancy in bfr1Δ compared to the wild-type levels in three biological and two 
technical replicates of each with ±SD.  
2.7.2. Polysomes are stalled on ERG4 mRNA in bfr1mut6A and bfr1Δ strains.  
The ribosome affinity purification only determines the overall association of ribosomes 
with mRNAs but does not give us any information on its distribution on mono- or 
polysomes. Since I have shown that the ribosome occupancy on ERG4 mRNA is 
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reduced upon loss of BFR1, I next asked whether this reduction is due to the change 
in distribution between mono- or polysomes of this mRNA. Together with our 
collaborators in Biozentrum, University of Basel in Switzerland (Dr. Nitish Mittal and 
Prof. Dr. Anne Spang), we performed polysome profiling experiment to determine the 
role of Bfr1p in associating of monosome or polysome to its candidate mRNAs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14. Bfr1p is required for efficient translation of ERG4 mRNA. A. Polysome profiles 
from wild type, bfr1mut6A and bfr1Δ compared to wild-type cells. (M) monosomes, (P) 
polysomes. B. Polysome association of ERG4 mRNA changes in bfr1mut6A and bfr1Δ. 
Sucrose density gradient fractionation was used to separate monosomes and polysomes, and 
RNAs from the fractions were quantified by qRT-PCR. Results are displayed as the fold 
change ratio of polysomes/monosomes for four mRNAs (normalized to ACT1 levels) from 
three independent experiments with ±SD. An asterisk indicates P <0.05. (ns) nonsignificant. 
 Logarithmically growing cells of wild type, bfr1Δ and bfr1mut6A strains were treated 
with CHX (100µg/ml) before harvesting and lysates were prepared and processed for 
separation of mono- and polysome fractions by sucrose density gradients. The 
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mRNAs pooled from mono- and polysome fractions were then quantified by qRT-PCR. 
The distribution of free ribosomal subunits, monosomes and polysomes in wild type, 
bfr1Δ and bfr1mut6A is similar as judged by fractionation profiles (Figure 2.14 A). IN 
contrast, an increased distribution of ERG4 (p<0.0299) and OSH7 (p<0.0178) to the 
polysome fraction was observed in bfr1mut6A cells when compared to the wild type 
cells. A similar pattern was seen in bfr1Δ (Figure 2.14 B). In addition, I have seen an 
increase of MID2 mRNA on polysomes but with a lesser significance (P<0.0708). The 
low expression of Erg4p as seen by western blot and in microscopy experiments and 
the increase of ERG4 on polysomes suggest that the polysomes are stalled on these 
mRNAs in both bfr1mut6A and bfr1Δ. Therefore, I conclude that Bfr1p plays a role in 
efficient elongation of polysomes on ERG4 mRNA during translation at ER. 
2.7.3. Bfr1p interacts transiently with ribosomes. 
The Bfr1 protein has been shown to co-purify with polysomes (Lang et al. 2001). 
However, it was unclear whether Bfr1p directly binds to ribosomes or it co-purifies with 
polysomes because it binds mRNAs during translation. To answer this, I performed 
co-immunoprecipitation of Rps3p, a small ribosomal subunit protein with Bfr1p. I 
performed immunoprecipitation using a commercially available GFP binder (GFP- MA 
Trap) system and co-immunoprecipitated Rps3p in Bfr1-yeGFP and bfr1mut6A-
yeGFP cells. A wild type untagged strain served as a control for specificity of 
immunoprecipitations. 
Although Bfr1p co-purifies with ribosomes, the western blot analysis of co-
immunoprecipitations revealed that there is no direct interaction between Bfr1p and 
ribosomes as all the Rps3p was seen in flow through fractions but not in IP fractions 
(Figure 2.16 A). Since I did not cross link the proteins in our lysates, I concluded that  
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Figure 2.16. Bfr1p interaction with ribosomes is transient. A. Bfr1p does not coprecipitate the 
small ribosomal subunit protein Rps3p indicating Bfr1p interaction with ribosomes is unstable. 
A representative image of three independent experiments from Bfr1pyeGFP 
immunoprecipitations. (I) Input, (IP) immunoprecipitation, (FT) flow through. B. Bfr1p 
interaction with ERG4 mRNA is increased upon translation. Immunoprecipitation was 
performed from the lysates of cells expressing Bfr1p-yeGFP and wild-type cells to co-
precipitate ERG4 mRNA with or without AUG and levels were quantified by qRT-PCR. Binding 
of ERG4 mRNA lacking an AUG (-AUG) is reduced by 43%. Data are represented as fold 
change ratio of the IP versus mock from three independent replicates with ± SD. 
 
Bfr1p possibly interacts with ribosomes in transient manner or indirectly via mRNA on 
translating ribosomes. 
2.7.4. Bfr1p interacts with ERG4 mRNA during translation. 
So far, I have established that Bfr1p binds to ERG4 mRNA and mutations in RNA-
binding sites of Bfr1p reduces this binding. However, I did not find any evidence of 
direct interaction of Bfr1p with ribosomes or this interaction might be too transient to 
detect. Therefore, I wanted to investigate whether ERG4 mRNA interaction with Bfr1p 
occurs during translation. To investigate this, I constructed a plasmid expressing 
ERG4 lacking the start codon (-AUG) and transformed it into a strain expressing Bfr1-
yeGFP. The co-immunoprecipitation of Bfr1p-yeGFP was performed for wild type 
ERG4 mRNA and -AUG ERG4 mRNA. A wild type untagged strain was used to control 
for non-specific immunoprecipitation. 
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The qRT-PCR revealed a reduction in -AUG ERG4 mRNA compared to wild type 
ERG4 mRNA suggesting that interaction of Bfr1p with ERG4 is translation dependent 
(Figure 2.16 B). However, a significant amount of -AUG ERG4 mRNA is still bound to 
Bfr1p confirming that Bfr1p is part of ERG4 mRNP complex during translation. 
Discussion 
 
42 
 
3. Discussion 
The Bfr1 protein was first reported as a high-copy suppressor of brefeldin A with a 
possible role in secretion and ploidy maintenance (Jackson and Képès 1994). 
However, later studies emphasized its functions as an RNA-binding protein regulating 
mRNA metabolism (Lang et al. 2001, Hogan et al. 2008, Kramer et al. 2014, Lapointe 
et al. 2015). Recent high-throughput studies have revealed the interacting residues of 
Bfr1p cross-linked to RNAs (Kramer et al. 2014). Bfr1p was proposed to play a role in 
multiple pathways including secretion, ploidy control, mRNA binding, P-body 
formation, and translation, but all previous studies were performed in BFR1 deletion 
cells (Jackson and Képès 1994, Xue et al. 1996, Weidner et al. 2014 and Simpson et 
al. 2014). Therefore, the RNA-binding functions of Bfr1p in terms of its physiological 
importance remains elusive. 
Here, I report that Bfr1p acts as a translational regulator by efficiently elongating 
polysomes on mRNAs or efficient translocation proteins that are translating at the ER 
(e.g. ERG4). Additionally, I show that Bfr1p has at least two distinct functions; a) via 
Bfr1p-RNA interaction to control translational regulation and b) via Bfr1p-
protein interaction to regulate cell ploidy, brefeldin A sensitivity and P-body formation.  
3.1. The loss of interaction of Bfr1p with RNA does not explain the phenotypes 
of bfr1Δ. 
Subcellular fractionations and fluorescence microscopy demonstrated that Bfr1p 
localizes to both the cytoplasm and the perinuclear endoplasmic reticulum (Lang et al. 
2001). Here, the authors also report the association of Bfr1p with polysome complexes 
in an RNA-dependent manner. A similar distribution pattern was shown for another 
yeast RBP, Scp160p (Wintersberger et al. 1995). Our lab has previously shown that 
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Khd1p, yet another yeast RBP associated with the ER via binding to its RNA (Syed et 
al. 2018). Since Bfr1p interacts with mRNAs translating at the ER, I investigated 
whether the ER localization of Bfr1p is RNA dependent and demonstrated that Bfr1p 
localizes to the ER in an RNA dependent manner (Figure 2.2). Further evidence for 
this was obtained from mutagenesis of either one of the conserved residues (F239) or 
all the six residues together, as Bfr1p’s enrichment redistributes from ER to the 
cytoplasm (Figure 2.4. A, C, D). This indicates that Bfr1p localizes to ER by binding 
to mRNAs that are translated on the surface of the ER. 
3.1.1. RNA-binding of Bfr1p vs P-bodies induction in bfr1Δ. 
Upon environmental stress, cells constantly regulate its proteome for its survival and 
to regain its normal growth conditions. The transcription is regulated to maintain the 
mRNA copy number protein abundance is determined by the mRNA translation and 
stability. To respond to the stress, the mRNAs are translationally attenuated stored in 
the membrane less bodies in the cytoplasm called P-bodies (Parker and Sheth 2007). 
During late phase of glucose starvation, Bfr1p was reported to target several mRNAs 
(e.g. RPS16A) to P-bodies (Simpson et al. 2014). Here, the authors also showed that 
Bfr1p localizes to P-bodies and interacts with the P-bodies components Dcp2 and 
Xnr1p via RNA.  
Similarly, under normal growth conditions, Bfr1p together with Scp160p, protects 
mRNAs from translocating to P-bodies by blocking access to P-body components. 
Loss of BFR1 induces P-body formation because mRNAs are now more accessible to 
the P-body components (Weidner et al. 2014). Surprisingly, mutations in RNA-binding 
residues do not induce premature P-bodies as seen in bfr1Δ, suggesting that loss of 
RNA-binding of Bfr1p is not important for the P-body formation (Figure 2.5). 
Discussion 
 
 
44 
 
3.1.2. A role of RNA-binding of Bfr1p in ploidy maintenance? 
One of the first observed phenotypes of bfr1Δ cells are defects in chromosome 
segregation and increased ploidy of the cells (Jackson and Képès 1994). A similar 
observation was also made cells deleted for SCP160 and WHI3 (Wintersberger et al. 
1995, and Schladebeck and Mösch 2013). Whi3p is an RNA-binding protein with an 
RRM domain that binds, among others to the CLN3 mRNA, which codes for a G1 
cyclin that coordinates cell size and G1/S transition (Gari et al. 2001). Our lab has 
previously shown that the KH13-14 domains of Scp160 are necessary for the RNA-
binding of Scp160p (Hirschmann et al. 2014). However, truncation of the KH10-14 
domains of Scp160p does not alter the ploidy (Cheng Mathew HK, 2018). Similar to 
the Scp160p, the RNA-binding mutants of Bfr1p does not change the ploidy of cells 
remains haploid (Figure 2.6) suggesting the increase in ploidy upon loss of BFR1 is 
independent from its RNA interactions. Bfr1p and Scp160p have also been identified 
as translational repressors of specific mRNAs (e.g. POM34) in the cells with defects 
in the spindle pole body duplications (SPB) (Sezen et al. 2009). Moreover, Bfr1p 
interacts with the Bbp1p, an SPB protein and this interaction is independent of RNA 
(Sezen et al. 2009). Taken together, this suggests that the role of Bfr1p in ploidy 
maintenance is based on protein-protein and not protein-RNA interactions.  
3.1.3. RNA-binding of Bfr1p vs BFA sensitivity. 
In eukaryotic cells, mRNAs encoding for secretory proteins are first translocated into 
the ER during translation for correct folding and modifications. Then most of these 
proteins are delivered to the Golgi apparatus for further modifications and to the 
plasma membrane for secretion (Guo et al. 2014, Guo et al. 2017).  Since the majority 
of Bfr1p bound mRNAs encodes secreted or endomembrane proteins, I tested if the 
loss of interaction between Bfr1p and mRNAs has any consequence on the secretion 
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pathway. High-copy expression of Bfr1p rescues cells from brefeldin A sensitivity, and 
all RNA-binding mutants show a similar rescue (Figure 2.7). This suggests that the 
proposed function of Bfr1p in secretion is not due to its interaction with translating 
mRNAs, rather it can be a consequence of interactions of Bfr1p with other RNAs or 
due to the protein-protein interactions of Bfr1p.  
Taken together, my results suggest that loss of RNA-binding of Bfr1p is not associated 
with the published phenotypes that show up upon deletion of BFR1, including ploidy 
control, brefeldin A sensitivity and formation of P-bodies. This also suggests that the 
localization of Bfr1p at the ER is not required to achieve these functions. 
3.2. ERG4 mRNA binds to Bfr1p but localizes to the ER independently. 
 
Several hundreds of Bfr1p-binding mRNAs were identified by high-throughput studies 
such as immunoprecipitations of RBPs followed by microarray analysis (RIP-Chip; 
Hogan et al. 2019), cross-linking and immunoprecipitation (CLIP; Mitchell et al. 2013), 
or RNA tagging (Lapointe et al. 2015). These studies investigated Bfr1p-mRNA 
interaction at a global level. However, no follow-up studies have been performed on 
Bfr1p’s interaction with individual mRNAs. Therefore, I tested five mRNA binders of 
Bfr1p that are significantly enriched in these high-throughput analyses and encode 
proteins associated with the phenotypes of bfr1Δ cells. Although mRNA stability is not 
affected (Figure 2.8) by loss of Bfr1p, co-immunoprecipitation of Bfr1p coupled with 
qRT-PCR demonstrated that ERG4 mRNA binds to Bfr1p at least in part via its known 
RNA contact sites, as mutations in these sites reduce this binding (Figure 2.9). The 
ERG4 mRNA is translated at the surface of the ER (Lapointe et al. 2015) and encodes 
an ER membrane protein with seven predicted transmembrane domains. Therefore, 
this mRNA must be targeted to the ER for its translation. mRNA localization to the ER 
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can be mediated by RBPs independent of their translation or by the SRP-targeting 
pathway. Our lab has previously demonstrated that two yeast proteins, She2p (Schmid 
et al. 2006) and Khd1p (Syed et al. 2018) are necessary for targeting their mRNA 
partners to the ER. In contrast, loss of BFR1 has no implications on the localization of 
ERG4 mRNA to the ER (Figure 2.10 A, B). This indicates that the Bfr1p binds to ERG4 
mRNA at the ER and does not participate in its localization.  
3.3. Bfr1p promotes local translation of mRNAs at the ER. 
Translational control of mRNAs is one of the important mechanisms by which a cell 
regulates its proteome. For example, if an unfolded protein accumulates, the rate of 
protein synthesis is reduced as these unfolded proteins become toxic to the cells 
Walter and Ron 2011). Similarly, an increased translation of certain mRNAs is required 
when cells exposed to the stress conditions (e.g. heat shock response) (Liu and Chang 
2008). RNA-binding proteins play a crucial role in regulating translation of mRNAs 
either by repressing or enhancing translation (Moore and von Lindern 2018, 
Abdelmohsen 2012). Since, Bfr1p binds to several ER translated mRNAs, its 
involvement in translation has already been proposed in previous studies (Lang et al. 
2001 and Lapointe et al. 2015).  
Although ERG4 mRNA localization to the ER is not dependent on Bfr1p, Erg4p-yeGFP 
localization at ER is severely impacted in cells deleted in BFR1 (Figure 2.11 A, B, 
C).  Erg4p-yeGFP predominantly localized at ER in wild type cells, whereas a faint 
signal from Erg4p-yeGFP was seen in the cytoplasm in bfr1Δ cells. However, replacing 
Bfr1p by the RNA-binding mutant (bfr1mut6A) has no effect on Erg4p expression and 
localization This implies that Bfr1p controls the expression of Erg4p independent from 
its interaction with the mRNA. The downregulation of Erg4p in bfr1Δ cells is not caused 
its vacuolar degradation as the deletion of PEP4 and BFR1 together do not increase 
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Erg4p levels or result in accumulation in the vacuole. Since Bfr1p mimics several 
functions of Scp160p, and ERG4 mRNA also binds to Scp160p (Hogan et al. 2008), I 
tested whether the loss of SCP160 show similar effect on the expression of Erg4p. 
However, I did not find any effect on the expression of Erg4p in scp160Δ cells 
suggesting ERG4 is a specific target of Bfr1p.   
ER-Associated Degradation (ERAD) is a mechanism where misfolded proteins of the 
ER are ubiquitylated by Hrd1p before re-translocated to the cytoplasm and eventually 
degraded by 26S proteasomes (Baldridge and Rapaport 2016). The Erg4p has seven 
predicted transmembrane domains and it is inserted into the ER membrane by 
simultaneously during translation. Therefore, the low expression of Erg4p in bfr1Δ cells 
is possibly due to misfolding of Erg4p in the absence of Bfr1p and hence it is 
redistributed to the cytoplasm for degradation. If this is true, the deletion of HRD1 
should result in the accumulation of misfolded Erg4p as it cannot be ubiquitylated for 
degradation. Here, I report that by inhibiting 26S proteasomes and deleting HRD1 
(bfr1Δ hrd1Δ) a strong accumulation of Erg4p confirming that Erg4p is indeed 
misfolded in absence of Bfr1p and it is degraded by ERAD pathway (Figure 2.12).  
The rate of translation of mRNAs depends on the number of (poly) ribosomes occupied 
on that mRNA and how efficiently ribosomes are elongating on these mRNAs. One of 
the rate-limiting steps for translation is either by inhibiting translation initiation or 
inhibiting translational elongation by stalling polysomes on these mRNAs. To shed 
more light on the reduction in Erg4p levels in the absence of Bfr1p, I applied 
Ribosome-affinity purifications (RAP) to purify ribosomes together with actively bound 
mRNAs. Consistent with the low expression of Erg4p, I found that the ribosomal 
occupancy on ERG4 mRNA is reduced suggesting Bfr1p might limit the ribosome 
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loading during translation (Figure 2.13). However, with this approach, I can only 
determine the number of ribosomes on ERG4 mRNAs but not the distribution of free-
floating ribosomes, monosomes, and polysomes. Therefore, I performed polysome 
profiling to understand how Bfr1p is important for the distribution of ribosomes during 
translation. Contrasting to the low expression of Erg4p in bfr1Δ cells, the polysome 
profiles of bfr1Δ or bfr1mut6A clearly demonstrate a strong shift in the distribution from 
monosome to polysomes (Figure 2.14 B). This is only possible if polysomes are 
stalled on these mRNAs resulting in less protein production. A similar observation was 
made for Scp160p where the number of polysomes on PRY3 mRNA was increased 
while protein was down-regulated (Hirschmann et al. 2014).  
 
 
 
 
 
 
 
Figure 3. Working model of Bfr1p in translational regulation. The cytoplasmic Bfr1p interacts 
with mRNAs that are to be translated by ER-bound ribosomes as a complex together with 
Scp160p. Once at the ER membrane, Bfr1p and Scp160p support efficient elongation of the 
mRNA. Mutations in RNA-binding residues of Bfr1p or the loss of BFR1 reduces the elongation 
efficiency, causing accumulation of polysomes on the mRNA, protein misfolding and elevated 
ER stress. In the absence of Bfr1p several proteins of the UPR pathway are down-regulated 
leading to degradation of misfolded proteins. 
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Consistent with the proposed role of Bfr1p in regulation of translation, a recent study 
from Castells-Ballester et al. (2019) showed that Bfr1p regulates the translation of 
Pmt1 and Pmt2, which are crucial for the unfolded O-mannosylation (UPOM). With 
ribosome profiling approach, the authors revealed that several mRNAs are 
translationally downregulated in bfr1Δ cells. Like PMT1 and PMT2, most of these 
mRNAs encode secretory proteins, proteins involved in ergosterol biosynthesis 
(including ERG4) and proteins of ER quality control.  
In addition, Bfr1p has been linked to the UPR (Travers et al. 2000 and Low et al. 2014) 
and might act as a checkpoint for synthesis of several proteins during elevated ER 
stress (Low et al. 2014) by regulating their translational efficiency. 
Taking together data from previous studies and from this study on Bfr1p, I propose 
that Bfr1p acts as a translational enhancer for mRNAs at the ER membrane either by 
increasing the efficiency of elongating polysomes or efficient folding of newly 
synthesized proteins (Figure 3). 
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4. Materials and Methods 
4.1. Materials 
4.1.1. Antibodies 
Antibodies were diluted in PBS-T (1x PBS + 0.1% Tween-20) per blot, 3-5 ml of 
antibody solution was used. 
Primary antibodies 
Name Host Dilution Source 
GFP  Mouse   1:5000  Covance 
GFP  Rabbit  1:2500  Invitrogen 
HA (clone 3F10)  Rat  1:3000  Roche 
Myc (9 E10)  Mouse  1:3000  Roche 
Pgk1  Mouse  1:7500  Invitrogen 
Scp160   Rabbit  1:10000 Gift from M. Seedorf, Heidelberg. 
Sec61 (Serum)  Rabbit  1:7500 Gift from M. Seedorf, Heidelberg. 
Rps3  Rabbit  1:10000  Gift from M. Seedorf, Heidelberg 
Secondary antibodies 
 
Name Host Dilution Source 
Anti-Mouse (IR)  Goat  1:10000  LI-COR 
Anti-Rabbit (IR)  Goat  1:10000  LI-COR 
Anti-Rat (IR)  Goat  1:10000  LI-COR 
Anti-Mouse (HRP)  Sheep  1:10000 Amersham ECL  
Anti-Rabbit (HRP)  Donkey  1:10000 Amersham ECL 
 
4.1.2. Chemicals 
Acros Organics D-Glucose monohydrate 
AppliChem Bacto peptone 
Bacto yeast extract 
Biomol Salmon sperm DNA (ss DNA) 
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Carl Roth 1,4-Dithiothreitol (DTT) 
2-mercaptoethanol 
Agarose ULTRA 
Acryl-Bisacrylamide 
Cycloheximide 
Dimethyl sulfoxide 
Glycerin 
Lithium Acetate 
Magnesium Chloride Hexahydrate 
Phenylmethylsulfonylfluoride (PMSF) 
Polyethylene glycol (PEG) 
Potassium Chloride 
TEMED 
Aminoacids 
Ammonium persulfate (APS) 
D-Galactose 
Ethylene Diamine Tetraacetic acid (EDTA) 
Sodium dodecyl sulfate (SDS) Sorbitol 
Sucrose 
Tris base 
Triton X-100 
Tween-20 
Fermentas Deoxynucleotide triphosphate Mix (dNTPs) 
FORMEDIUM Yeast Nitrogen Base 
Thermo Scientific Brefeldin A (eBioscience) 
Roche cOMPLETE, Mini, EDTA-free Protease inhibitor Cocktail tablets 
Sigma-Aldrich Proclin-300, MG132, EDAC 
 
4.1.3. Commercial Kits 
Macherey and Nagel NucleoSpin Gel and PCR clean up 
NucleoSpin Plasmid 
NucleoSpin RNA II isolation kit 
Thermo Scientific High-Capacity cDNA Reverse Transcription kit 
Fast SYBR Green Master Mix 
Polysciences, Inc. PolyLink Protein Coupling kit using EDAC 
 
4.1.4. Consumables 
Chromo Tek GFP-Trap_MA beads 
Carl Roth Cover slips 
Objective slides 
Glass beads 
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GE Healthcare Protein G Sepharose 4 Fast flow beads 
ECL Western blotting Substrate 
LI-COR Biosciences PVDF Membranes 
Nitrocellulose Membranes 
SARSTEDT AG & Co. Centrifuge tube 50 ml, 15 ml 
CryoPure Storage Systems 
High quality pipette tips 
High quality serological pipettes 
Micro Tubes SafeSeal 2 ml, 1.5 ml 
PCR reaction tubes 
Semi-micro cuvette 
 
4.1.5. Enzymes 
NEB Restriction digestion enzymes 
Agilent Technologies Herculase II Fusion DNA Polymerase 
Amsbio Zymolse 20T, Zymolase 100T 
GENAXXON Taq Polymerase 
Thermo Scientific/Fermentas Proteinase K 
Fast-Digest Restriction enzymes 
RiboLock RNase Inhibitor 
T4 DNA Ligase 
PageRuler Prestained Protein Ladder 
PageRuler Unstained Protein Ladder 
PageRuler DNA ladder (100 bp, 1 Kb) 
RNse Inhibitor 
RNAse A 
Promega Q1-RNase free DNase 
 
4.1.6. Equipment 
Alpha Innotec Fluorchem® FC2 
Bio-Rad Mini-PROTEAN Tetra Electrophoresis System 
PowerPac HC Power Supply 
ChemiDoc MP 
MyCycler Thermo Cycler 
SNAP i.d. ™ System 
Eppendorf Centrifuge 5415R 
Centrifuge 5702 
Centrifuge 5810R 
Pippettes P1000, P200, P20, P10 
BIO ER ThermoCell Mixing Block MB-102 
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BECKMAN COULTER Ultracentrifuge rotor SW 40 Ti 
Ultracentrifuge TLA-120.2 
CytoFLEX Flow Cytometer 
LI-COR Biosciences Odyssey Infrared Imaging System 
Stuart Scientific Gyro rocker 
Scientific Industries, Inc. Vortex-Genie 2 
SPEX® Inc Bead mill 
IKA Vibrax VXR basic 
VISITRON SYSTEMS VisiScope Live Cell Imaging System 
Thermo Scientific The StepOne Plus Real-Time PCR System 
Ultracentrifuge rotor TH-641 
ZEISS Axio Examiner 
SPEX Inc Freezer Mill/Mixer Mill 
 
4.1.7. Oligonucleotides 
RJO Name Sequence (5‘- 3‘) Purpose 
5238 Bfr1_R38A_Fw GAAATCGGTTTAATTGCCAAGCAAATCGATCAA Mutation PCR 
5239 Bfr1_R38A_Rw TTGATCGATTTGCTTGGCAATTAAACCGATTTC Mutation PCR 
5240 Bfr1_H79A_Fw CGTAGAAGCAACATTGCCGACTCTATTAAGCAA Mutation PCR 
5241 Bfr1_H79A_Rw TTGCTTAATAGAGTCGGCAATGTTGCTTCTACG Mutation PCR 
5242 Bfr1_K138A_Fw GAAAAACTACTAGTCGCCGAAATGCAATCTTTG Mutation PCR 
5243 Bfr1_K138A_Rw CAAAGATTGCATTTCGGCGACTAGTAGTTTTTC Mutation PCR 
5244 Bfr1_F211A_Fw AAAAGACAAACTTTAGCCAACAAACGTGCTGCC Mutation PCR 
5245 Bfr1_F211A_Rw GGCAGCACGTTTGTTGGCTAAAGTTTGTCTTTT Mutation PCR 
5246 Bfr1_Y225A_Fw AAGCGTGACGAATTAGCCAGTCAAATCAGACAG Mutation PCR 
5247 Bfr1_Y225A_Rw CTGTCTGATTTGACTGGCTAATTCGTCACGCTT Mutation PCR 
5248 Bfr1_F239A_Fw GACTTTGACAACGAAGCCAAATCATTCAGAGCC Mutation PCR 
5249 Bfr1_F239A_Rw GGCTCTGAATGATTTGGCTTCGTTGTCAAAGTC Mutation PCR 
4924 Bfr1::HA C-terminal 
S3_Fw 
AAAAGATTGAAAGAACAGGAAGAGTCTGAAAAAG
ATAAAGAAAATCGTACGCTGCAGGTCGAC 
Gene tagging 
4925 Bfr1::HA C-terminal 
S2_Rw 
AATGAAGAAAGATCAGGAGAAAAATTTTTTTCTAC
TTCAGGTTTAATCGATGAATTCGAGCTCG 
Gene tagging 
5587 Eag1 Termi Bfr1_Fw GGCCGGCCGACCTGAAGTAGAAAAAAATTTTTC Cloning 
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5588 Terminator Bfr1 
SacI_Rw 
CGAGCTCGGAGGAAAGAATTGGCTGGTAAG Cloning 
6367 Bfr1 
promotor_KpnI_Fw 
GGGGTACCGGGCGTAAGAACGAATTTGAAG Cloning 
5432 yEGFP-Stop-NheI-Rw GCCGCTAGCTTATTTGTACAATTCATCCATACC Cloning 
5589 S3_bfr1 1-397AA_Fw ccaacactaattgctactttggccgaattagacgtaactgtcccaatcCG
TACGCTGCAGGTCGAC 
Gene tagging 
5590 S2_bfr11-397AA_Rw agtaatgaagaaagatcaggagaaaaatttttttctacttcaggtttaAT
CGATGAATTCGAGCTCG 
Gene tagging 
3006 Bfr1_ko_S1_for TCAACGTAATAGCATATTTTCTAACAACACAGCCA
TTGCCCGTACGCTGCAGGTCGAC 
Gene deletion 
3007 Bfr1_ko_S2_rev TGAAGAAAGATCAGGAGAAAAATTTTTTTCTACTT
CAGGTATCGATGAATTCGAGCTC 
Gene deletion 
5828 ERG4 deltion Fw S1 CAGATACGGATATTTACGTAGTGTACATAGATTA
GCATCGCTATGCGTACGCTGCAGGTCGAC 
Gene deletion 
5820 ERG4 C-term tag Fw 
S3 
GAGTATTGTAAACATTGCCCTTACGTCTTTATTCC
TTATGTTTTCCGTACGCTGCAGGTCGAC 
Gene tagging 
5821 ERG4 C-term tag Rw 
S2 
ACTGTAAAATAAGTTAATGAAGTGGATAGAAAAA
GAAAATAACTA ATCGATGAATTCGAGCTCG 
Gene tagging 
5826 ERG6 deltion Fw S1 AAAAAAACAAGAATAAAATAATAATATAGTAGGCA
GCATAAGATGCGTACGCTGCAGGTCGAC 
Gene deletion 
5827 ERG6 deltion Rw S2 ATATATCGTGCGCTTTATTTGAATCTTATTGATCT
AGTGAATTTAATCGATGAATTCGAGCTCG 
Gene deletion 
6320 ERG4_NewMS2_F: ATGAGTATTGTAAACATTGCCCTTACGTCTTTATT
CCTTATGTTTTCTAGccgctctagaactagtggat 
Gene tagging 
6321 ERG4_NewMS2_R: ATATACAAACTGTAAAATAAGTTAATGAAGTGGAT
AGAAAAAGAAAATAAgatatcacctaataacttcgtatag 
Gene tagging 
6603 PEP4 -del-S1-Fw CTAGTATTTAATCCAAATAAAATTCAAACAAAAAC
CAAAACTAACATGCGTACGCTGCAGGTCGAC 
Gene deletion 
6604 PEP4 -del-S2-Rw TAGATGGCAGAAAAGGATAGGGCGGAGAAGTAA
GAAAAGTTTAGCTCAATCGATGAATTCGAGCTCG 
Gene deletion 
2509 SCP160_ko_ fw S1 TAAAATATACTTCCCACACCCCCTCCTTCCATTAT
AACTGCACGTACGCTGCAGGTCGAC 
Gene deletion 
2510 SCP160_ko_ rev S2 GCCAAAATCTATATTGAAAAAAATTGGTTTCAAAG
AGCTTGTATCGATGAATTCGAGCTC 
Gene deletion 
6324 IMH1_qPCR_Fw_Set 
2 
ATTGACGACGCAGTGGATAC qPCR 
6325 IMH1_qPCR_Rw_Set 
2 
CTGGAATTTCCGAGTTCTGC qPCR 
6326 RUD3_qPCR_Fw_Set 
1 
TTTCGTGTCCATACCCAGAG qPCR 
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6327 RUD3_qPCR_Rw_Set 
1 
CCGGCCTGTTGTTTCTTATC qPCR 
6332 ERG4_qPCR_Fw_Set 
2 
TGCCATGTGGACCTTGTATG qRT-PCR 
6333 ERG4_qPCR_Rw_Set 
2 
GTCATGATCCTCCCAAAACG qRT-PCR 
6334 OSH7_qPCR_Fw_Set 
1 
TGCAGAACAAACGAGTCACC qPCR 
6335 OSH7_qPCR_Rw_Set 
1 
CCATCATTGCAGCACTTGAG qPCR 
6338 SGM1_qPCR_Fw_Set 
1 
GGGAAGGGGAATCAATGAAC qPCR 
6339 SGM1_qPCR_Rw_Se
t 1 
GGCCGTTAGAATTCGATAGC qPCR 
2920 Act1_qPCR_1_Fw TCAGAGCCCCAGAAGCTTTG qPCR 
2921 Act1_qPCR_1_Rw TTGGTCAATACCGGCAGATTC qPCR 
4139 18S_qPCR_Fw TCAACACGGGGAAACTCACC qRT-PCR 
4148 18S_qPCR_Rw CTAAGAACGGCCATGCACCA qRT-PCR 
4488 MID2_qPCR_Fw ATGGAGCAAAGCTCCCTTTT qPCR 
4489 MID2_qPCR_Rw GCTCTCCACCGCTATTGGTA qPCR 
5568 Spike-qPCR_Fw CACACTCATCAGCGACACGA qPCR 
5569 Spike-qPCR_Rw CCAAAGCGGTGACTTTCTGC qPCR 
6527 BamHI_ERG4 
_102_Fw 
CGCGGATCCATTTGTGCGGAATTTTATCAC Cloning 
6528 ERG4_3UTR_Hindiii_
Rw 
CCCAAGCTTGAATTTTCAAAGAATGACTTG Cloning 
3008 Bfr1_3'UTR_rev CATGAGGAAAGAATTGGCTGG Gene tagging 
4918 bfr1_5'UTR_fw TAACTGATCTCGACGACGTTG Gene tagging 
 
4.1.8. Plasmids 
Name Short description Source 
RJP1870 pRS415-HDEL-DsRED (Bevis and Glick 2002) 
RJP2121 pET296-YcpLac111-CYC1p-1xMCPNLSSV40-2-xyegfp (Tutucci et al. 2017) 
RJP1809 Edc3-mCh URA3 Cen (Buchan et al. 2008) 
RJP1686 YCp50-SCS2-TMD-2xRFP (Loewen et al. 2007) 
RJP2000 pRS316-pBFR1-Bfr1 FL-yeGFP This study 
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RJP2199 pRS316-pBFR1-bfr1mutR38A-yeGFP This study 
RJP2200 pRS316-pBFR1-bfr1mutH79A-yeGFP This study 
RJP2061 pRS316-pBFR1-bfr1mutK138A-yeGFP This study 
RJP2201 pRS316-pBFR1-bfr1mutF211A-yeGFP This study 
RJP2202 pRS316-pBFR1-bfr1mutY225A-yeGFP This study 
RJP2062 pRS316-pBFR1-bfr1mutF239A-yeGFP This study 
RJP2209 pRS316-(-AUG) ERG4 This study 
RJP2203 YEplac181-pBFR1-Bfr1 FL-yeGFP This study 
RJP2204 YEplac181-pBFR1-bfr1mut6A-yeGFP This study 
RJP2205 YEplac181-pBFR1-bfr1mut5A-yeGFP This study 
RJP2206 YEplac181-pBFR1-bfr1mut4A-yeGFP This study 
RJP2207 YEplac181-pBFR1-bfr1mut3A-yeGFP This study 
RJP2208 YEplac181-pBFR1-bfr1mut2A-yeGFP This study 
RJP148    pRS316 (URA3, CEN6) (Janke et al. 2004) 
RJP143 YEplac181 (LEU2), 2µm (Gietz and Schiestl 2007) 
 
4.1.9. Yeast (Saccharomyces cerevisiae) strains 
Name Essential genotype Plasmid(s) Origin 
RJY358 MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-
11,15 ura3 
- 
 
RJY925 MATa/MATalpha, ade2-1/ade2-1 trp1-1/trp1-1 
can1-100/can1-100 leu2-3,112/leu2-3,112 his3-
11,15/his3-11,15 ura3 GAL psi+ 
- 
 
RJY4680 MATa Bfr1p-yeGFP::HIS3MX6 - This study 
RJY5142 MATa Bfr1p(1-397)-yeGFP::KanMX6 - This study 
RJY5204 MATa bfr1mut6A-yeGFP::HIS3MX6 - This study 
RJY4626 MATa bfr1::HIS3MX6 - This study 
RJY5146 MATa RJP1870 This study 
RJY5148 MATa Bfr1p-yeGFP::HIS3MX6 RJP1870 This study 
RJY5417 MATa Bfr1p(1-397)-yeGFP::KanMX6 RJP1870 This study 
RJY5419 MATa bfr1mut6A-yeGFP::HIS3MX6 RJP1870 This study 
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RJY5145 MATa bfr1::HIS3MX6 RJP1870  RJP2062 This study 
RJY5144 MATa bfr1::HIS3MX6 RJP1870  RJP2061 This study 
RJY5421 MATa bfr1::HIS3MX6 RJP1870  RJP2199 This study 
RJY5422 MATa bfr1::HIS3MX6 RJP1870 RJP2200 This study 
RJY5423 MATa bfr1::HIS3MX6 RJP1870  RJP2201 This study 
RJY5424 MATa bfr1::HIS3MX6 RJP1870  RJP2202 This study 
RJY5434 MATa RJP1809 This study 
RJY5435 MATa bfr1::HIS3MX6 RJP1809 This study 
RJY5436 MATa Bfr1p-yeGFP::HIS3MX6 RJP1809 This study 
RJY5437 MATa Bfr1p(1-397)-yeGFP::KanMX6 RJP1809 This study 
RJY5438 MATa bfr1mut6A-yeGFP::HIS3MX6 RJP1809 This study 
RJY5425 MATa erg6:KanMX6 - This study 
RJY5426 MATa erg6::KanMX6 bfr1::HIS3MX6 RJP2203 This study 
RJY5427 MATa erg6::KanMX6 bfr1::HIS3MX6 RJP2204 This study 
RJY5428 MATa erg6::KanMX6 bfr1::HIS3MX6 RJP2205 This study 
RJY5429 MATa erg6::KanMX6 bfr1::HIS3MX6 RJP2206 This study 
RJY5430 MATa erg6::KanMX6 bfr1::HIS3MX6 RJP2207 This study 
RJY5431 MATa erg6::KanMX6 bfr1::HIS3MX6 RJP2208 This study 
RJY5260 MATa ERG4-12xMS2V6::KanMX4 RJP2121  RJP1686 This study 
RJY5262 MATa bfr1::HIS3MX6  ERG4-
12xMS2V6::KanMX4 
RJP2121  RJP1686 This study 
RJY5432 MATa Erg4-yeGFP::kITRP1 RJP1870 This study 
RJY5433 MATa Erg4-yeGFP::kITRP bfr1::HIS3MX6 RJP1870 This study 
RJY5439 MATa Erg4-yeGFP::kITRP bfr1::HIS3MX 
pep4::KanMX6 
- This study 
RJY5440 MATa Erg4-yeGFP::kITRP scp160::HIS3MX6 - This study 
RJY4683 MATa Bfr1p-6HA::KanMX Scp160-
myc9::HIS3MX6 
- This study 
RJY3206 MATa Khd1-GFP::KanMX4 - (Syed et al. 
2018) 
RJY3687 MATa RPL16a-TEV-ProtA::HIS3MX6 - (Hirschmann et 
al. 2014) 
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RJY4855 MATa RPL16a-TEV-ProtA::HIS3MX 
bfr1::KanMX4 
- (Hirschmann et 
al. 2014) 
RJY5441 MATa Bfr1p-yeGFP::HIS3MX erg4::KanMX4 RJP2209 This study 
RJY5469 MATa Erg4-yeGFP::kITRP bfr1mut6A-
6HA::KanMX4 
RJP1870 This study 
RJY5470 MATa Erg4-yeGFP::kITRP bfr1::HIS3MX6 
hrd1::KanMX4 
- This study 
 
4.2. Methods 
All standard biochemical, microbiological and molecular biology techniques were 
based on Sambrook J. et al, 2001. Commercial Kits were used according to 
manufacturer’s instructions. Standard buffers were prepared as described (Sambrook, 
2001). 
4.2.1. Basic Methods 
4.2.1.1. Agarose gel electrophoresis and gel extraction 
As a standard in most cases, I used 1.0 % of agarose gels. Agarose was added to 
TAE buffer to the required concentration and then heated in a microwave oven until 
agarose was completely melted. The solution was cooled to 60°C, then 2-3 µl of 
10,000x stock solution of GelRed were added and the gel poured into a casting tray 
containing a multiwall comb. The gel was solidified at room temperature. For PCR 
product gel extraction, bands were cut out using 70% intensity of the UV illumination 
at 365 nm. DNA extraction was carried out by the NucleoSpin Gel and PCR clean up 
kit (Macherey & Nagel) according to manufacturer’s instructions. 
4.2.1.2. Restriction digestion 
Vector and insert DNA were digested in a following reaction mixture. In most cases, 
Fast digest enzymes (Thermo Scientific) were used for reaction. 
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Insert DNA mix (20 μl):                                                          Vector DNA mix (30 μl): 
2 μl (0.2-0.5 μg)                                                                     2 μl (~1 μg) 
2 μl 10x buffer                                                                        2 μl 10x buffer 
1 μl enzyme 1                                                                        1 μl enzyme 1 
1 μl enzyme 2                                                                        1 μl enzyme 2 
14 μl sterile water                                                                  24 μl sterile water 
 
The reaction mixtures were incubated at temperatures as described by the 
manufacturer's manual. After the incubation, DNA was extracted from the gel or PCR 
cleaned up by the NucleoSpin Gel and PCR clean up kit. 
4.2.1.3. Ligation of DNA fragments 
The molar ratio between vector and insert DNA was either 1:1, 1:2, 1:3 or 1:5 
depending on the size of the insert and the presence of blunt ends in the insert. The 
online ligation calculator tool from NEB (https://nebiocalculator.neb.com/#!/ligation) 
was used for setting up the ligation reaction. 
The ligation of digested DNA was performed as follows: 
Ligation mix (20 μl): 
10x ligation buffer 2 μl 
T4 DNA ligase 2 μl 
DNA vector 2-4 μl (~100-200 ng) 
DNA insert 7 μl (~450-600 ng) 
Sterile water 7-5 μl 
The ligation mix was incubated overnight at 25°C for 30 min and afterwards directly 
used for E. coli transformation or stored at -20°C. 
Materials and Methods 
 
 
60 
 
4.2.1.4. Overlap extension PCR 
Some of the plasmids were constructed by the “Overlap Extension PCR” method 
(Bryksin, Matsumura 2010). This method allows ligation of linear DNAs which have at 
least 15-30 bp complementary sequences at their 5’ and 3’ ends by using in vivo 
homologous recombination in E. coli. 
4.2.2. SDS-PAGE and Western blotting 
4.2.2.1. SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed using the Mini-Protean® Tetra System (BIO-RAD). In most cases, a 10% 
or 12% separating gel was used with 4% stacking gel. Samples were heated at 65ºC 
for 10 min or sometimes 95°C for 5 minutes before loading onto the gel. The samples 
were run at 100 V for 90-120 min and until the bromophenol blue reached the bottom 
of the gel. Afterwards, the gel was either prepared for Coomassie or Silver staining or 
for Western blotting. 
4.2.2.2. Coomassie staining 
For the staining of polyacrylamide gels using Coomassie Brilliant Blue R-250 the gel 
was immersed in Coomassie staining solution and warmed in a microwave oven for 
20 to 30 seconds, then kept on shaker for at least 45 mins. Then stain was removed 
by shaking overnight until no more background was visible. 
4.2.2.3. Western blotting 
Protein transfer onto a polyvinylidene fluoride transfer membrane (PVDF; LI-COR) 
was performed using a wet blot procedure with a transfer cell (BIO-RAD). Both gel and 
Whatman-paper slices were covered with transfer buffer (0.25 M Tris, 1.92 M glycine, 
pH 8.6 ± 0.2) for 5 min. The PVDF membrane was activated by shortly rinsing it in 
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methanol. A transfer sandwich was set up (2 thin Whatman-papers sheets, membrane, 
gel, 2 thin Whatman-papers sheets) and the proteins were transferred for 45 min at 12 
V. After disassembly, the membrane was blocked with 5% blocking buffer (5% non-fat 
dry milk powder in PBS-Tween 20; PBST) when directly using the SNAP i.d.TM 
system for immunoblotting. The antibodies for detection are listed in section 4.1. After 
blocking, the membrane was incubated with primary antibody for 10 min at room 
temperature, and then washed 3x with PBST to remove the unbound primary 
antibodies. Subsequently, incubation with the secondary antibody was performed for 
10 min at room temperature. The membrane was washed 3x with PBST and 
visualization of proteins was performed using an enhanced chemiluminescence kit 
(ECL-kit, GE Healthcare) or IR fluorescence. Signals were detected using the 
Fluorchem® FC2 (Alpha Innotech) or ChemiDoc (Bio-Rad) chemiluminescence 
imaging system and for IR fluorescence LI-COR imaging system. 
4.3.  E. coli-specific techniques 
4.3.1 Chemical competent E. coli cells preparation 
Chemically competent E. coli cells were prepared from the strain One Shot™ TOP10 
(Invitrogen), which was grown in 50 ml Luria Bertani (LB) medium (for 100ml: 0.8 g 
bacto peptone, 0.5 g yeast extract, 1 g NaCl pH 7.4) at 37°C in a shaking incubator 
until an optical density of 0.4-0.6 at OD600 was reached. Then the cells were cooled on 
ice for 15 min and collected by centrifugation (10 min, 4,500 rpm, 4°C). The pellet was 
resuspended in 1 ml ice-cold 50 mM CaCl2/10% glycerol. After re-centrifugation, the 
pellet was resuspended in 2 ml of ice-cold calcium chloride solution. Then the cells 
were pelleted and resuspended in one fourth of the cell volume of 0.1 M CaCl2/10% 
glycerol. Aliquots of 50 μl were shock-frozen in liquid Nitrogen (LN2) and stored at -
80°C. 
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4.3.2 Plasmid-DNA extraction (Miniprep) 
High-quality bacterial plasmid-DNA was extracted with the Macherey-Nagel Miniprep 
Kit according to the manufacturer’s protocol. 
4.3.3 Transformation of competent E. coli cells 
The One Shot™ TOP10 competent cells were thawed on ice for about 5-10 min. Then 
the DNA (5-50 ng of plasmid DNA or 20 μl of the ligation mix) were added to 50 μl of 
cells and incubated on ice for 10-15 mins, then plated on antibiotic containing LB agar 
plates and incubated at 37°C overnight. Individual bacterial colonies were picked and 
inoculated in 3 ml of LB medium containing antibiotics (e.g. 100 μg/ml Ampicillin) and 
grown for 8 h or overnight (37°C, shaker) in order to perform plasmid extractions 
(Miniprep). 
4.3.4 PCR for colony screening 
Bacterial colony PCR was carried out by picking up a bacterial clone with the help of 
a 10 μl pipette tip and added to the master mix. 
Reaction mixture (total volume 20 μl): 
10x PCR buffer S with 15mM MgCl2 (Genaxxon) 2.0 μl   
25 mM dNTPs 0.5 μl               
Forward + Reverse primer (10 µM each) 1 + 1 μl            
25 mM MgCl2 0.5 μl                 
Taq polymerase 0.2 μl            
Sterile water 14.8 μl             
 Program:       
Step 1:       95°C – 5 min 
Step 2:       95°C - 30 sec 
Step 3:       54°C - 30 sec 
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Step 4:       68°C - (1 min/Kb) 
Step 2-4:   30 cycles 
Step 5:      68°C - 10 min 
Step 6:      4°C   ∞ 
 
4.3.5. Construction of specific plasmids 
Plasmid RJP2000 (pRS316-pBFR1-Bfr1 FL-yeGFP) was created as follows. First, a 
PCR product spanning from the BFR1 promoter region to the C-terminal yeGFP was 
generated using oligonucleotides RJO6367 and RJO5432 and genomic DNA of 
RJY4680 (Bfr1p-yeGFP::HIS3MX6) as a template. The product was digested with 
restriction enzymes KpnI and NheI whose sites were introduced by the 
oligonucleotides. RJP148 (pRS316) was digested with KpnI and XbaI and both 
fragments ligated. The 3’UTR region of BFR1 was amplified separately with 
oligonucleotides RJO5587 and RJO5588 using genomic DNA of strain RJY358 and 
digested with restriction enzymes EagI and SacI whose restriction sites were 
introduced with the oligonucleotides. The intermediate construct was digested with 
restriction enzymes EagI and SacI and the digested PCR product was ligated in to 
generate RJP2000. 
Plasmids containing the complete BFR1 gene with point mutations (RJP2199; 
bfr1mutR38A-yeGFP, RJP2200; bfr1mutH79A-yeGFP, RJP2061; bfr1mutK138A-
yeGFP, RJP2201; bfr1mutF211A-yeGFP, RJP2202; bfr1mutY225A-yeGFP and 
RJP2062; bfr1mutF239A-yeGFP) were created from a pRS316 vector carrying BFR1 
by an overlap extension PCR method (see 4.2.1.4) with respective oligonucleotides. 
High copy number plasmids carrying BFR1 or its mutant constructs were created as 
follows. Firstly, full-length BFR1 fused to the yeGFP coding region was released from 
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RJP2000 (pRS316-pBFR1-Bfr1 FL-yeGFP) by digestion with KpnI and SacI and 
ligated into the vector YEplac181 to create plasmid YEplac181-pBFR1-Bfr1 FL-yeGFP 
(RJP2203). To generate plasmids carrying multiple mutations (RJP2208; YEplac181-
pBFR1-bfr1mut2A-yeGFP, RJP2207; YEplac181-pBFR1-bfr1mut3A-yeGFP, 
RJP2206; YEplac181-pBFR1-bfr1mut4A-yeGFP, RJP2205; YEplac181-pBFR1-
bfr1mut5A-yeGFP, RJP2204; YEplac181-pBFR1- bfr1mut6A-yeGFP), two-step 
overlap extension PCR was performed with oligonucleotides RJO6367 and RJO5432 
together with mutation specific primers. The corresponding PCR products contained 
KpnI and SacI restriction sites at their ends. PCR products with lower numbers of 
mutations were used as templates for generation of additional mutations. The PCR 
products were then digested with KpnI and SacI and ligated into YEplac181. 
Plasmid RJP2209 (carrying AUG-less ERG4) was created as follows. A PCR product 
of the ERG4 coding region (lacking the part encoding the first 101 amino acids), 
together with the 3’UTR, was amplified by PCR with oligonucleotides RJY6527 and 
RJY6528, introducing BamHI and HindIII restriction sites. The digested product was 
ligated into vector pRS316. 
4.3.6 Sequencing and analysis 
Sequencing was done by Eurofins and GATC GmbH. The plasmids and primers were 
prepared and/or chosen as recommended by the company. The analysis of the 
sequences was done by using the software SnapGene (from GSL Biotech) and ApE- 
A plasmid Editor (by M. Wyane Davis). 
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4.3.7. Glycerol stocks and storage 
To store bacteria for long-term, 500μl of cells from an overnight culture were 
transferred into a cryo-tube and mixed with 50% (w/v) glycerol to a final concentration 
of 15% (w/v). The cells were shock-frozen with liquid nitrogen and stored at -80°C. 
4.4. S. cerevisiae-specific techniques 
4.4.1 Polymerase chain reaction 
Gene knock-out or introduction of tags in yeast were performed by PCR-based 
methods (Knop et al, 1999; Janke et al, 2004). Herculase (Agilent Technologies) was 
used for PCR reactions for its proof-reading ability and accuracy. PCR products were 
purified using the Macherey & Nagel PCR clean-up Kit. 
4.4.1.1 Standard PCR for generation of deletion or tagging cassettes 
The standard PCR reaction was prepared as follows: 
Reaction mixture (total volume 50 μl): Program: 
  
10x PCR buffer Herculase with 10mM MgCl2 5.0 μl   
dNTPs 10 mM 2.5 μl               
DMSO 2 µl 
Forward + Reverse primer (10 µM each) 1 + 1 μl            
Template (50-250 ng/μl) 1 μl                 
Herculase enzyme 0.5 μl            
Sterile water 37 μl             
 
Program:         
Step 1:       95°C – 5 min 
Step 2:       95°C - 30 sec 
Step 3:       54°C - 30 sec 
Step 4:       68°C - (1 min/Kb) 
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Step 2-4:    32 cycles 
Step 5:   70°C - 10 min 
Step 6:   4°C   ∞  
 
4.4.2 Yeast colony PCR 
To identify correct colonies after the transformations, a single yeast colony was 
scraped off from a fresh plate and suspended in 100 μl of 200 mM lithium acetate 
containing 1% SDS. Then the mixture was incubated at 70°C for 15 min. After 
adding 300 μl of 100% ethanol and vortexing, the DNA was collected Methods 81 by 
centrifugation at 13,000 rpm for 3 min. The precipitated DNA was dissolved in 100 μl 
TE and cell debris were spun down at 13,000 rpm for 1 min. 1 μl of the supernatant 
was used for PCR (Looke et al, 2011; Balaji TM, 2014). 
Reaction mixture (total volume 20 μl) Program: 
10x PCR buffer S with 15mM MgCl2 (Genaxxon) 2.0 μl   
25mM dNTPs 0.5 μl               
Forward + Reverse primer (10 µM each) 1 + 1 μl            
25mM MgCl2 0.5 μl                 
DNA template 1 µl 
Taq polymerase 0.2 μl            
Sterile water 13.8 μl             
  
Program:         
Step 1:       95°C – 5 min 
Step 2:       95°C - 30 sec 
Step 3:       54°C - 30 sec 
Step 4:       68°C - (1 min/Kb) 
Step 2-4:   20 cycles 
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Step 5:      68°C - 5 min 
Step 6:      4°C   ∞ 
 
4.4.3. Transformation of yeast cell 
4.4.3.1 One-step yeast transformation with plasmids 
Transformation of yeast with plasmids was done as described (Chen et al, 1992 and 
Balaji TM, 2014). Cells were inoculated in 5 ml of medium and incubated overnight or 
used directly by scraping off a fresh plate. The cell suspension (1 ml) was pelleted by 
centrifugation and the pellet was resuspended by vortexing briefly in 100 μl of one-
step buffer (0.2 M lithium acetate, 40% PEG 4000, 100 mM DTT). An aliquot of single 
stranded salmon sperm DNA (ssDNA) was thawed on ice, heated for 5 min at 95°C, 
and directly cooled down on ice to make the DNA linear. 20 μg ssDNA and 100 - 500 
ng plasmid DNA was added to the cell-buffer suspension and mixed by vigorous 
vortexing. Then the mixture was incubated for 30 min at 45°C. After this heat shock, 1 
ml YEPD was added, cells were resuspended and pelleted at 10,000 rpm for 15 sec. 
The supernatant was discarded, and the pellet was carefully resuspended in 1 ml 
YPED medium. 100-200 μl of the suspension were plated onto the corresponding 
selective plate and incubated at 30°C. Colonies appeared after 2-3 days. 
4.4.3.2 High-efficiency yeast transformation 
Yeast cells were transformed with PCR products for genomic integration via 
homologous recombination by high efficiency transformation method (Schiestl & Gietz, 
1989). A single colony of yeast was inoculated in 10 ml YEPD medium or drop out 
medium and rotated on a wheel overnight at 30°C. Subsequently 50 ml of YEPD 
medium or drop out medium was inoculated with an overnight culture to an OD600 of 
0.2-0.3. Cells grew for two generations until OD600 reaches 1. The cells were then 
harvested by centrifugation at 2,500 rpm for 5 min. The supernatant was discarded, 
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the cells were washed with 10 ml water and the pellet was resuspended in 1 ml of 
freshly prepared 100 mM lithium acetate. After centrifugation at top speed for 30 sec, 
the supernatant was removed, and the cells were resuspended in 400 μl of 100 mM 
lithium acetate. An aliquot of ssDNA was thawed, boiled for 5 min at 95°C and quickly 
chilled on ice. For one transformation mix, 50 μl of the suspension was transferred into 
a new 1.5 ml reaction tube. After centrifugation lithium acetate was completely 
removed and the transformation mix (240 μl (50% w/v) PEG, 36 μl of 1 M lithium 
acetate, 25 μl of ssDNA (2 mg/ml), 50 μl water with 0.5-3 μg linear DNA) was added 
to the cell pellet. The mixture was vortexed vigorously until the pellet was completely 
resuspended. The mixture was then incubated for 30 min at 30°C, treated for 23 min 
at 42°C and centrifuged at 8,000 rpm for 30 sec. The transformation mix was removed, 
and the pellet resuspended in 1 ml of water or medium. 100-200 μl of the suspension 
was plated onto the corresponding selective medium. In the case of Kanamycin 
marker, cells were recovered on a YEPD plate overnight at 30°C and replica plated 
onto YEPD+G418 (geneticin) plates. Colonies appeared after 2-3 days. 
4.4.4. Genomic DNA extraction from yeast cells 
In order to use genomic DNA as a template for PCR, genomic DNA was extracted 
from yeast as the follows. A big loop of yeast was scraped off a fresh plate, 
resuspended in 1 ml of water and pelleted at 1,000 rpm for 5 min at 4°C. The pellet 
was resuspended in 200 μl of DEB (DNA extraction buffer, 1% SDS, 100 mM NaCl, 
10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0 and 0.2% Triton X-100). 500 μl of acid-
washed sterile glass beads (0.4 mm diameter) and 200 μl of 
Phenol/Chloroform/Isoamylalcohol (24:24:1) were added to the cells and the mixture 
was vigorously shaken using a vibrax shaker for 5 min (top speed, 4°C). The lysate 
was mixed with 200 μl of TE, vortexed for 30 sec and centrifuged at 12,000 rpm for 10 
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min at RT. After transferring 200 μl of the supernatant to a new Eppendorf cup filled 
with 750 μl of 100% ethanol and after vortexing the mixture, the genomic DNA was 
precipitated by centrifugation at 12,000 rpm for 10 min at RT. Ethanol was removed 
by aspiration. The tube was centrifuged again to remove residual ethanol. The pellet 
was dried for about 10 min by leaving the tube open and finally resuspended in 50 μl 
of TE buffer. The DNA was directly used for PCR or stored at -20°C. 
4.4.5. Quick alkaline lysis of yeast cells  
One loop of cells from fresh plates was mixed with 1 ml of water, 150 μl 1.85 M of 
NaOH and 7.5% β-Mercaptoethanol and chilled on ice for 15 min. 150 μl 50% TCA 
were added and the mixture centrifuged at 14,000 rpm for 15 min at 4°C. The 
supernatant was discarded and 50 μl of High Urea (HU) buffer (8 M urea, 5% SDS, 20 
mM Tris pH 8.8, 1.5% DTT, bromophenolblue) was added to each pellet. The mixture 
was then incubated for 10 min at 65°C with shaking. The supernatant was collected 
by centrifugation at 14,000 rpm for 1 min and used for further experiments (e.g. 
Western blotting). 
4.4.6. Construction of specific yeast strains 
The strain with BFR1 point mutations was generated as follows. We first mutated 
F239A using the genomic DNA from strain RJY4680 (Bfr1p-yeGFP::HIS3MX6) as a 
template and oligonucleotide pairs RJY4918 and RJY5248 (from the 5’UTR region of 
BFR1 to F239 position), and RJY5249 and RJY3008 (from F239 position to 3’UTR 
region of BFR1). These two separate PCR products were then amplified in an overlap 
extension PCR reaction using the oligonucleotides RJY4918 and RJY3008. This 
intermediate PCR product served as a template for the subsequent introduction of 
individual mutations (R38A, H79A, K138A, F211A) using mutagenic oligonucleotides. 
After generating the final product with all six mutations, the linear DNA was 
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transformed into RJY358 to generate the strain RJY5204 (bfr1mut6A-
yeGFP::HIS3MX6). Strains RJY5260 (ERG4-12xMS2V6::KanMx4) and RJY5262 
(bfr1Δ::HIS3MX6, ERG4-12xMS2V6::KanMx4) were generated as described (Haim-
Vilmovsky and Gerst 2009; Tutucci et al. 2017). BFR1 gene deletion strains used to 
express Bfr1p from plasmids were created after transformation of the corresponding 
plasmids to avoid diploidization as often seen in bfr1∆. 
4.4.7. Yeast strains storage at -80°C 
For long term storage of yeast, 500 μl of a cell suspension from an overnight culture 
were mixed in a cryo-tube with 50% (w/v) glycerol to a final concentration of 25% (w/v). 
Alternatively, some cells were scraped off from the fresh plate and transferred to 15% 
glycerol tubes. The cells were flash-frozen in liquid nitrogen and stored at - 80°C. 
4.4.8. Yeast extract preparation and subcellular fractionation 
50 OD600 units of logarithmically growing yeast cells were harvested and washed once 
with ice cold water. For subcellular fractionation into membrane and cytoplasmic 
fractions, we followed the protocol described in (Syed et al. 2018). In brief, cells were 
washed two times with cold potassium phosphate buffer (100 mM potassium 
phosphate pH 7.5, 1.2 M sucrose) and lysed using glass beads (four pulses of 60 
seconds with breaks of 60 seconds on ice) in 500 µl low salt lysis buffer 1 (20 mM 
HEPES/KOH pH 7.5, 140 mM potassium acetate, 1 mM magnesium acetate, 1 mM 
DTT, 250 mM sucrose, 1x cOmpleteTM, Mini, EDTA-free Protease Inhibitor Cocktail 
). Cell debris was removed by centrifugation (twice at 800 xg for 5 minutes). The 
resulting whole cell extract (WCE) was diluted to 0.1 μg/μl of protein as determined by 
the Bradford assay and 200 μl was fractionated at 6,000 xg for 5 minutes (M6), 18,000 
xg for 30 minutes (M18) and supernatant (C). Pellets M6 and M18 were resuspended 
in 200 μl low-salt lysis buffer 1 and 15 μl were used for SDS-PAGE followed by western 
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blotting. For RNAse A treatment experiments, after removing cell debris and dilution 
to 0.2 μg/μl, lysates were divided into two equal parts and one part was treated with 
RNAse A (100 µg/ml) for 30 minutes at room temperature. The other part was 
considered as a mock treatment. 
4.4.9. Confocal microscopy 
In vivo imaging of fluorescent labelled proteins was carried out from inoculation of 
single colonies into SC or SDC medium containing 2% glucose and overnight growth 
at 30° C. Logarithmically growing cells were harvested and re-suspended in 100µl of 
fresh medium. Cells were spread on thin agarose pads containing SC or SDC with 2% 
glucose and grown for 30 minutes at 30° C before observing in microscope (ZEISS 
AxioExaminer equipped with a CSU spinning disc confocal unit; Visitron Systems, 
Germany). Images were acquired with a 63x oil objective using VisiView software 
(Visitron Systems). Post image processing was performed using Fiji software as 
described (Syed et al. 2018; Hermesh et al. 2014). For ERG4 mRNA localization, 
images were acquired with each containing at least 60 cells. For P-bodies analysis, 
logarithmically growing cells were harvested, washed once with sterile water before 
cells were spread on agarose pads containing SDC medium without glucose and 
grown at 30°C for 30 min to induce P-bodies. 
4.4.10. Co-immunoprecipitations of protein and RNA 
For protein-mRNA co-precipitations, experiments were performed as described (Syed 
et al. 2018) with the following changes. 100 OD600 units of cells were harvested and 
resuspended in 8-10 µl/OD600 of lysis buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 
mM EDTA, 0.1% Triton X-100, 1x Protease inhibitor cocktail and 0.5 U/µL Ribolock 
RNase inhibitor). Glass bead lysis was performed, and cell debris was removed by 5 
minutes centrifugation at 5000 xg at 4° C. Protein concentrations were measured and 
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200 µg of lysates were subjected to immunoprecipitation with GFP-Trap_MA magnetic 
beads (Chromotek) at 4° C for two hours on a rotating wheel. The beads were blocked 
prior to the immunoprecipitations with blocking buffer (10 mM Tris-HCl pH 7.5, 150 
mM NaCl, 2 mM EDTA, 0.1% Triton X-100, 0.1 mg/ml E.coli tRNA and 0.4 mg/ml 
Heparin). Captured beads were washed 3x with 500 µl of wash buffer (10 mM Tris-
HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, and 0.1% Triton X-100) and resuspended 
beads with 125 µl of HPLC grade water (Sigma). 75µl of the bead slurry was used for 
SDS-PAGE and western blotting. RNA extraction was carried out with the remaining 
50 µl of beads, to which 50 ng of spike RNA (in vitro transcribed Arabidopsis 
phosphoribulokinase RNA) had been added. For extraction 5 µl of 3 M Sodium acetate 
pH 5.2, 2.5 µl of 20% SDS and 50 µl of phenol/chloroform/isoamylalcohol (PCI) pH 4.5 
(Roth, Germany) was added and the mixed sample centrifuged at maximum speed for 
30 min at 4° C. Nucleic acids were precipitated overnight at -80° C with 20 µg of 
glycogen and 100 µl of 96% ethanol and RNA was resuspended in 20 µl of RNAse 
free water before continuing with cDNA synthesis and qPCR. 
4.4.11. Co-immunoprecipitations of proteins 
Co-immunoprecipitations of proteins were performed with Protein G Sepharose® 4 Fast 
Flow beads (GE Healthcare) or GFP-Trap_MA magnetic beads (Chromotek). 100 
OD600 units of cells were harvested and resuspended in 8-10 µl/OD600 of lysis buffer (10 
mM Tris-HCl pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.1% Triton X-100, 1x Protease 
inhibitor cocktail and 0.5 U/µL Ribolock RNase inhibitor). Glass bead lysis was 
performed and cell debris was removed by 5 minutes centrifugation at 5000 xg at 4° 
C. Protein concentrations were measured and 200 µg of lysates were subjected to 
immunoprecipitation with GFP-Trap_MA magnetic beads or Protein G Sepharose® 4 
Fast Flow beads at 4° C for two hours on a rotating wheel. The beads were blocked 
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prior to the immunoprecipitations with blocking buffer (10 mM Tris-HCl pH 7.5, 150 
mM NaCl, 2 mM EDTA, 0.1% Triton X-100, 0.1 mg/ml E. coli tRNA and 0.4 mg/ml 
Heparin). For some experiments, prior to the immunoprecipitations RNAse treatment 
was performed with 100 µg/ml of RNAse A for 30 min at 37° C. Lysates were pre-
cleared with the beads overnight 4° C on a rotating wheel. Beads were removed by 
centrifugation (twice at 1,000 xg) and then pre-cleared lysates were supplemented 
with respective antibody with beads and incubated at 4° C for 4 hours on a rotating 
wheel. After washing, the beads were resuspended in 1x Laemmli buffer and 
continued with SDS-PAGE and western blot analysis. 
4.4.12. RNA extraction from yeast cells 
Total RNA was extracted from 20 OD600 units of yeast cells. Glass beads lysis was 
performed in 500 µl of Cross buffer I (0.3 M NaCl, 10 mM Tris-HCl pH 7.5, 1 mM EDTA, 
0.2 % SDS) and 400 µl of phenol:chloroform:isoamylalcohol by four pulses of 120 
seconds with interrupts of 60 seconds on ice. After centrifugation for 10 minutes at full 
speed the upper phase was transferred to a new tube and nucleic acids precipitated 
with ethanol for 30 min at -20° C. Total RNA pellets were washed and resuspended in 
20 µl of HPLC grade water before proceeding to cDNA synthesis and qPCR. 
4.4.13. cDNA synthesis (RT-PCR) 
Reverse transcription reactions for all the experiments were performed as described 
in (Syed et al. 2018) with some modifications. In brief, 1 µg of RNA samples were 
treated with RQ1 DNase (Promega) for 37°C for 30 minutes. 10x RT buffer, 10x 
Random primers, Reverse Transcriptase enzymes (all from Applied biosystems), 
25mM dNTPs were mixed with 10 μl of DNAse treated RNA to the total reaction volume 
of 20 μl. 1 μl Ribolock was added to the reaction. A ‘minus RT’ reaction was carried 
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out by adding all the components except the reverse transcriptase. Reaction mixtures 
were placed in the PCR block. 
PCR program: 
25°C - 10 min 
37°C - 2 h 
85°C - 10 min 
4°C - ∞ 
After PCR, cDNA samples were diluted to 1:10 and 1:100 with HPLC water for qRT-
PCR analysis. For long term storage samples were stored at -20°C.and reverse 
transcription reactions performed using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). 
4.4.14. Quantitative real time PCR (qRT-PCR) 
Quantitative RT-PCR (qRT-PCR) was performed with a StepOnePlus Real-Time PCR 
System in 10 µl reactions containing 2.5 µl of cDNA samples at 1:25 or 1:50 dilutions. 
Target specific primers were designed with Primer3 software (Rozen and Skaletsky 
2000). The PCR profile included an initial denaturation for 10 min at 95°C, followed by 
35 cycles of amplification, comprising denaturation at 95°C for 15 sec and 
annealing/elongation at 60°C for 1 min. After each cycle, a single fluorescence 
measurement was taken. All reactions were run in duplicates and included a negative 
control (-RT). All reactions were performed from a minimum of three biological 
replicates and two technical replicates of each. Quantification was performed by 
comparative ∆∆Ct method (Livak and Schmittgen 2001; Syed et al. 2018) and values 
were normalized via the spiked-in RNA or via ACT1 mRNA signals. 
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4.4.15. Ribosome affinity purifications (RAP) 
Ribosome affinity purification (RAP-IP) to determine mRNAs or tRNAs bound to 
ribosomes was performed as described in (Hirschmann et al. 2014; and Hirschmann, 
2015). 
4.4.15.1. Coupling of microbeads to immunoglobulin using carbodiimide 
Coupling of 0.75 μm microbeads (Polysciences) to PP-64K unspecific IgG (Millipore) 
using carbodiimide was performed essentially as prescribed by the manufacturer. 
Briefly, 12.5 mg of microparticles (or 500 µL) was pipetted into a microcentrifuge tube 
from a 2.5% w/v suspension solution of the beads. Particles were pelleted at 1,000 xg 
for 10 min, and the supernatant was evacuated. Particles were resuspended in 400 
μL of Coupling buffer (50 mM MES pH 5.2,0.05% Proclin-300) and pelleted again as 
above. Then the particles were resuspended again in 170 μL of Coupling buffer, and 
a 200mg/mL EDAC (carbodiimide) solution which was prepared just before use by 
dissolving 5 mg EDAC in 25 μL coupling buffer. 20 μL of the EDAC solution was then 
added to the particle suspension and followed by brief maximal vortexing. A protein 
equivalent of 300 μg, e.g. from 30 μL of a 10 mg/mL solution, IgG was added 
immediately, followed by brief vortexing and incubation on a thermomixer for 1-1.5h at 
RT and 850 rpm shaking. After incubation, the tube was centrifuged as described 
above and supernatant of ~ 220 μL was used to determine the coupling efficiency. The 
remaining pellet was then resuspended in 400 μL of Washing buffer (10 mM Tris pH 
8, 0.05% BSA, 0.05% Proclin-300) and used for the RAP experiments. 
4.4.15.2. Ribosome-affinity purification followed by IP (RAP-IP) 
100 mL of yeast cells were used to perform RAP experiments. One minute prior to 
harvest, cells were provided with 1mL of 10 mg/mL cycloheximide (CHX) stock added 
to 100 mL of culture to achieve translational arrest by a concentration of 0.1 mg/mL 
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CHX. 100 mL of yeast of each strain were harvested at OD600 of 0.5 in 50 mL Falcon 
tubes (Sarstedt) in aliquots of 50 mL and centrifuged for 5 mins at 3,000 rpm. Pellets 
were resuspended with a total of 10 mL of buffer A (20mM Tris–HCl, 140mM KCl, 2mM 
MgCl2,1% Triton X-100, 0.2 mg/ml heparin, 0.1 mg/ml CHX) in two aliquots of 5 ml. 
The aliquots were then pooled in a 14 mL Corex-equivalent plastic tube (Sarstedt) and 
centrifuged again as described above. After discarding the supernatant, cells were 
flash-frozen using liquid nitrogen and stored at -80°C. For RAP analysis, cells were 
thawed on ice and resuspended in 1 mL of buffer B (buffer A plus 0.5mM dithiothreitol 
(DTT), 1mM phenylmethylsulfonylfluoride (PMSF), 0.5 µg/ml Leupeptin, 0.2 µg/ml 
Pepstatin, 20 U/ml DNase I, 100 U/ml RiboLock (Fermentas)) in 14 mL plastic tube, 
and lysed using 1/3 vol. of 0.4 μm glass beads (Roth) by four cycles of (20s vortex at 
max speed – 90s cooling on ice) each. Then, crude extracts were transferred to 
microcentrifuge tubes and cleared by three subsequent centrifugation steps at 2,600 
– 8,600 – 13,500 xg at 4°C. Supernatants following the last centrifugation were brought 
to 1 mL with buffer B. The subsequent steps were performed in a cold room at 4°C. 
Four aliquots of IgG-coupled microbeads were used for each experiment. First, beads 
were blocked in 1 mL blocking buffer (buffer A supplemented with 0.4 mg/ml heparin, 
0.1 mg/ml Escherichia coli tRNA , and 1% BSA) for each aliquot, and shaken at 850 
rpm and RT for 10 mins and collected  by centrifuging for 10 mins at 1,000 xg. Then, 
the beads are washed once using 500μL of buffer A per aliquot (10 mins, 850 rpm, 
RT). Prior to centrifugation (10 mins at 1,000 xg, RT) the four aliquots were pooled in 
a 2mL microcentrifuge tube. During centrifugation, a thermomixer was pre-incubated 
to 4°C in the cold room. 250 μL of lysate was secured and stored at -80°C and later 
used as a lysate control. The remaining 750 μL of lysate was batch-incubated with the 
pelleted beads for 2h at 4°C and 850 rpm in the cold room. Following batch incubation, 
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the beads were collected for 2 mins at 3,000 xg, 4°C. Then the beads were washed 
four times with 1.5 mL buffer C (20mM Tris–HCl [pH 8.0], 140mM KCl, 2mM MgCl2, 
5% glycerol, 0.5mM DTT, 40 U/ml RiboLock (Fermentas)) by shaking at 750 rpm and 
4°C for 15 mins. Before the last washing step, the microcentrifuge tube was replaced 
with a fresh one to prevent nonspecific aggregation to tube walls. Beads were then 
resuspended in 207 μL of buffer C and Proteinase K (Thermo Fisher), and incubated 
for 40 minutes at 50°C. Following the cleavage, beads were pelleted for 5 mins at 
13,400 xg and 4°C. The eluted beads were secured and stored at - 80°C and later 
used for RNA extractions  
The RNA extraction was performed using phenol:chloroform (5:1) before re-extraction 
of the  aqueous phase with chloroform and precipitation in ethanol overnight at -20°C. 
For the quantification of mRNAs bound to the ribosomes, qRT-PCR was performed, 
and the enrichment of mRNAs determined using the ∆∆CT method. An enrichment of 
mRNAs from TAP purification (in wild-type and bfr1∆) was considered only if at least 
two-fold greater than from mock purification (strains without TAP tags). The % 
ribosomal occupancy of bfr1∆ was then plotted against wild type. 
4.4.16. Polysome profiling 
Separation of mono- and polysomes was done as described in (Mittal et al. 2017) and 
performed with three biological replicates of wildtype, bfr1Δ and bfr1mut6A strains. 
Logarithmically growing cells were treated with 100µg/ml cycloheximide (CHX) for 1 
minute, harvested by vacuum filtration and flash frozen with liquid nitrogen. Cells lysis 
was performed under cryogenic conditions using lysis buffer (20 mM Tris-HCl, pH 7.5, 
100 mM NaCl, 10 mM MgCl2, 1% Triton X-100, 0.5 mM DDT and 100 µg/ml of CHX) 
and a bead mill (Spex Inc., Metuchen, NJ, USA). Cell debris was removed by 
centrifugation for 3 min at 3,000 xg and 4 °C followed by 10,000 xg for 5 minutes at 4 
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°C. To separate monosomes and polysomes, 10 A260 units of lysates were loaded on 
pre-cooled 12 ml of 7% - 47% linear sucrose gradients (50 mM Tris-HCl, pH 7.5, 50 
mM NH4Cl, 12 mM MgCl2, 0.5 mM DTT, and 100 µg/ml CHX) and centrifuged at 35,000 
rpm for 3 hours at 4° C in a TH-641 rotor (Thermo Scientific) before collecting the 
monosome and polysome peaks. RNA was isolated by adding 5µl of glycogen and 
phenol:chloroform (5:1) before re-extraction of the  aqueous phase with chloroform 
and precipitation in ethanol overnight at -20°C. RNA pellets were resuspended in 30 
µl of HPLC grade water and processed for cDNA synthesis and qRT-PCR. 
4.4.17. Brefeldin A sensitivity drop assay 
A single colony of yeast cells was inoculated in 10 mL of YEPD or drop out medium 
and grown at 30°C overnight before diluting it into fresh medium of 20 mL in flask to 
grow until logarithmic phase. Cells were harvested by centrifugation at 2500 rpm, and 
room temperature. After that cells were washed once with sterile water. 1 OD600 units 
of cells was used for serial dilution and 3 µl of dilutions were plated on SDC-leu 
medium with or without 50 µg/ml brefeldin A. Cells were grown for 72 hrs at 30°C. 
4.4.18. Proteasomes inhibition by MG132 
To block the proteasomes, we have used commercially available proteasome inhibitor 
MG132 as described in Liu et al. (2007). Briefly, cells from a single colony was 
inoculated overnight in a synthetic medium containing 0.17% yeast nitrogenous base 
without ammonium sulfate and supplemented with 0.1% proline, appropriate amino 
acids, and 2% glucose as the carbon source. Cultures were reinoculated in 30 mL 
fresh media with 0.003% of SDS for 3 h at 30°C. Then 75 μM MG132 dissolved in 
DMSO or DMSO alone as a control was added to the cultures and grown for 30 min 
at 30°C before adding 100 μg/mL of CHX to the cultures to stop the translation. Cells 
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were harvested at 0, 30, and 60 min and processed for cell lysis and western blot to 
analyse the protein levels. 
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